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Leishmaniasis is a group of diseases caused by an obligate protozoan Leishmania and transmitted 
by sand flies. As a neglected tropical disease (NTD), leishmaniasis disproportionately affects the 
poorest populations and those living in rural, remote areas or conflict zones with limited or no 
access to health care. Manifesting in cutaneous, mucocutaneous or visceral symptoms, the 
diseases’ complexity and diversity across regions contribute to the challenges in the control 
efforts. Visceral leishmaniasis (VL) is fatal without treatment, and the indelible scars left by 
cutaneous leishmaniasis (CL) may have important psycho-social impact.  
Eastern Africa region currently bears most of the world’s VL burden. However, underestimation 
of true disease burden is likely, as the paucity of data from unstable contexts may contribute to 
inaccurate disease estimates. Both VL and CL are known to have limited geographic distribution 
but may show high variability inter- and intra-countries. Population movement due to conflict or 
drought, combined with weak or poorly functioning health system have led to epidemics and 
spread in new areas. Without vaccine or effective vector control, the pillar of control strategy in 
Africa remains diagnosis and treatment.  
Access to adequate, quality diagnostic and treatment services in Africa is challenging. The rk39 
rapid test is less accurate and treatment options are limited. A 17-day combination of antimonial 
and paromomycin is the first line treatment for VL in the region, requiring prolonged 
hospitalisation and increased economic burden for the patients and their households.  
Despite the progress in tackling NTDs, access to care for leishmaniasis is often taken for granted. 
Especially in Africa, access remains problematic and the current body of literature shows critical 
evidence gaps. Low coverage of the health services, accessibility and availability of quality care, 
limited diagnostic and therapeutic options along with inefficient procurement and supply remain 
significant challenges in the region. Delay in seeking treatment not only increase morbidity and 
mortality but also sustain transmission.  
The hypothesis informing the project is that access to care for leishmaniasis in Africa is still 
inadequate. The general objectives of this thesis are to improve our understanding on access to 
care in Africa, by documenting availability, affordability and accessibility of care, explore novel 
ways of enhancing such care, and provide insights into specific elements of access to formulate 
coherent policy recommendations for leishmaniasis in eastern Africa. Three specific objectives 
were formulated: the first is to update the disease burden, second to examine access issues 
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METHODS 
Four distinct methodologies were deployed in this research. First, systematic reviews (on 
cutaneous leishmaniasis epidemiological burden in sub-Saharan Africa and economic impact of 
leishmaniasis), along with context analysis (on access to care for VL in Somalia). The systematic 
review protocols were published and registered in PROSPERO and followed PRISMA guidelines.  
On the access upstream part, we conducted a landscape analysis to assess if the public-private 
partnership (PPP) was a solution to tackle neglected tropical diseases. An in-depth case study 
on miltefosine, the only oral drug for VL, was conducted to analyse its post-licensure access issues. 
On access downstream, we answered the research questions (a) What were the barriers at the 
health service level, their supply chain? and (b) What remains the barriers at the community level? 
through qualitative research methodologies. A series of in-depth interviews were conducted 
with main stakeholders at the global and national level from Ethiopia, Kenya, Somalia, South 
Sudan, Sudan and Uganda, as well with former VL patients, community leaders and health care 
workers from southern Gadarif, Sudan.  
 
MAIN RESULTS 
• Visceral leishmaniasis care in Somalia 
Somalia has suffered from protracted conflict since 1991 and VL has been reported in southern 
endemic foci. We reviewed evidence about VL epidemiology in Somalia and appraised control 
options within the context of this fragile state's health system. The sole VL control option is 
diagnosis and treatment, which are mostly provided by non-state actors. The availability of VL 
care in Somalia is limited and insufficient at best, both in coverage and quality. Precarious security 
remains a significant obstacle to reach VL patients in the endemic areas, and the true VL burden 
remains unknown. Innovative approaches in VL care provision, adapted to the context and 
without undermining the health system building process are needed. Existing tools for VL control 
should be deployed, and critically, efforts to overcome the limitations of the current VL diagnostic 
and treatment tools in conflict settings should continue.  
• Epidemiological burden of cutaneous leishmaniasis in sub-Saharan Africa 
We reported the state-of-the-art knowledge on CL epidemiology in sub-Saharan Africa. A 
synthesis from 54 included papers revealed that 13 of the 48 sub-Saharan African countries had 
reported CL. Historically, CL has been present for decades in both western and eastern Africa, but 
unfortunately, data are irregular and patchy. All studies were observational: 29 were descriptive 
case series (total 13,257 cases), and 24 followed a cross-sectional design. Only 22% of the studies 
were carried out post-2000. There is a high variability across methodologies, leading to difficulties 
to compare or combine data. The prevalence in hospital settings among suspected cases ranged 
between 0.1 and 14.2%. At the community level, CL prevalence varied widely between studies. 
Outbreaks of thousands of cases occurred in Ethiopia, Ghana, and Sudan. Polymorphism of CL in 
HIV-infected people is a concern. There is insufficient evidence to have accurate figures, and 
critical information gaps are population-based CL prevalence/incidence, risk factors, and its 
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socio-economic burden. It is critical to improve the current fragmented knowledge by increasing 
commitments to tackle CL and conduct better population studies in sub-Saharan Africa.  
 
• Understanding the economic impact of leishmaniasis in endemic countries 
We conducted a systematic review of cost-of-illness studies on leishmaniasis across different 
settings (Asia, Africa, and Latin America) and the consequences to households. Despite free 
provision of diagnostics and treatment in the public health care sector, VL cost of illness is a 
critical barrier in accessing care across different settings, due to both direct out-of-pocket 
payments and indirect costs of lost productivity. Between 11-57% of the annual household 
income was spent on VL-related expenses. VL leads to catastrophic health expenditure, continuing 
poverty and long-term indebtedness despite various coping strategies. The illness cost is 
decreasing due to shorter treatment regimens in Asia, but the situation remains challenging in 
Africa. Improvement of control tools is critical. There is a need to update cost estimates to inform 
policy-making and ensure sustainable solutions to reduce financial barriers to leishmaniasis care, 
especially in pursuing universal health coverage.  
• Why miltefosine – a life-saving drug for leishmaniasis – is unavailable for the patients 
who need it the most? 
Miltefosine, the only oral drug approved for the treatment of leishmaniasis, is considered as a 
success story of research and development (R&D) by a public-private partnership (PPP). Re-
purposed cancer drug in the 1990s, its development showed that PPP is a viable model for 
promoting R&D in NTDs. At the time, miltefosine constituted a breakthrough treatment. However, 
access to miltefosine post-licensure remains limited to date. Low availability and affordability 
have been vital issues globally. The initial PPP agreement which includes access to the public 
sector is not enforced. Shortages occurred due to inefficient supply chains and use of a sub-
standard product led to a high number of treatment failures and deaths. We argued that product 
development for neglected diseases should aim beyond the registration of the product and 
ensuring access downstream is imperative. The mechanism(s) to enforce framework and legal 
agreements between partners need to improve, and loopholes in R&D incentives – such as the 
Priority Review Voucher – needs fixing. Strategies to expand access to an NTD drug must address 
affordability as a key obstacle, along with supply-side strategies that assure availability.  
• Community perspectives on access barriers to leishmaniasis care in Gadarif, Sudan 
Through 24 in-depth interviews (IDI) and 29 focus group discussions (FGDs), with a total of 191 
participants, this qualitative study explored the barriers to access kala-azar care in southern 
Gadarif, Sudan. Our findings describe the multitude of difficulties people face when seeking kala-
azar care and illustrate the prevailing hardship in a rural Sudanese context. The various barriers, 
as experienced and narrated by study participants, is categorised in six emergent themes (the 
misconceptions, the difficult trajectories to get diagnosed, variable quality of care, taxing journey, 
gender inequalities and lack of control efforts). Access to health care is always a multi-dimensional 
phenomenon closely related to the health-seeking behaviour of the population. However, in this 
region, the perception of illness and care is predominantly shaped by poverty and other structural 
problems in an extremely resource-constrained setting. 
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• Exploring global and country-level barriers to effective supply of leishmaniasis in 
eastern Africa: a qualitative study 
An uninterrupted supply chain for leishmaniasis diagnostics and medicines is imperative. On the 
ground reality is different; quality-assured sources are limited, the procurement process is long, 
and shortages in health facilities deter care-seeking. Ensuring a reliable supply chain for VL has 
been chronically challenging due to the context and dependence on external support. From the 
stakeholders’ perspectives, barriers prevail along the supply (manufacturing and selection, 
forecasting, procurement and distribution) and health system level (financing, regulatory, 
coordination). Addressing the barriers requires a more unified approach. Our findings indicate 
that despite the diversity in each country's context, simultaneous efforts and collaboration in 
policy and implementation are required. Regional coordination and global leadership are vital. 
Commercial logic of companies needs more bridging towards public health needs in terms of price 
and availability. With commodities strictly procured by the public and not-for-profit entities, 
options such as pooled procurement are attractive, albeit hampered by lack of funding and 
commitment. Drug donations do not erase the need for sustainable access driven from the 
countries. Availability and procurement of diagnostics have been overlooked significantly. 
 
GENERAL DISCUSSION AND CONCLUSION 
Ensuring that all individuals suffering from leishmaniasis have prompt access to effective 
treatment remains a challenge for resource-constrained health systems. The works in this thesis 
provide insights into the complexity of access to care for leishmaniasis in Africa, ranging from 
problematic burden assessment and barriers at the global R&D landscape and further at health 
system and community levels. Care provision – the primary control strategy in this region through 
diagnosis and treatment – therefore needs to take into account the persisting barriers. Access 
programmes operate within complex health systems and contexts; therefore, any isolated 
strategy may not always or immediately translate into improved patient access. The access 
framework for leishmaniasis, i.e. care availability, affordability, quality and adoption/acceptance, 
as used in this thesis, could provide insights into future interventions. Measurement of access 
should be strived for and further evidence generated.  
The current efforts to control leishmaniasis in eastern Africa need to deal first and foremost with 
access to care, which sadly remains inadequate. Conflict-affected areas require innovative 
strategies. Developing improved diagnostic and treatment control tools is crucial, and so is 









La leishmaniasis es un grupo de enfermedades causadas por un protozoo (Leishmania) y 
transmitidas por flebótomos. Como enfermedad tropical desatendida (NTD, por sus siglas en 
inglés), la leishmaniasis afecta de manera desproporcionada a las poblaciones más pobres y a las 
personas que viven en zonas rurales, remotas o en zonas de conflicto con acceso limitado o nulo a 
la atención médica. Las distintas formas clínicas (cutánea, visceral), la complejidad y la 
distribución de la leishmaniasis en distintas regiones son algunos de los desafíos para controlar 
la enfermedad. La leishmaniasis visceral (LV) es mortal si el paciente no recibe tratamiento a 
tiempo, y las cicatrices dejadas por la leishmaniasis cutánea (LC) pueden tener un importante 
impacto psicosocial.  
Actualmente la mayor carga de LV se concentra en la región de África oriental aunque las cifras 
disponibles son probablemente una subestimación del número real de casos debido a la falta de 
datos fiables. Se sabe que tanto la LV como la LC tienen una distribución geográfica limitada, pero 
pueden mostrar una alta variabilidad tanto entre países como entre zonas en un mismo país. Los 
movimientos poblacionales debidos a conflictos o sequías, combinado con un sistema de salud 
débil o con un funcionamiento deficiente, provocan la expansión de la enfermedad a nuevas áreas 
y la aparición de epidemias. Al no existir una vacuna ni un control efectivo de vectores, el control 
de la leishmaniasis en África se sigue basando en el diagnóstico y el tratamiento de los casos. 
El acceso al diagnóstico y tratamiento adecuados y de calidad para la leishmaniasis es un reto en 
África. La prueba de diagnóstico rápido disponible (rK39 RDT) tiene una baja sensibilidad y las 
opciones terapéuticas son limitadas. La tratamiento combinado de antimoniales y paromomicina 
durante 17 días es el tratamiento de primera línea para la LV en África oriental. Este tratamiento 
requiere una hospitalización prolongada y representa una mayor carga económica para los 
pacientes y sus hogares. 
A pesar del progreso en la lucha contra las NTD, el acceso a la atención para la leishmaniasis sigue 
siendo problemático, especialmente en África. La literatura científica identifica deficiencias 
importantes como la baja cobertura de los servicios de salud, la falta de atención médica de 
calidad, las opciones diagnósticas y terapéuticas limitadas así como los problemas de suministro 
de estas herramientas. El retraso en iniciar el tratamiento no solo aumenta la morbilidad y la 
mortalidad, sino que también mantiene la transmisión de la Leishmania en las comunidades. El 
problema es que las barreras para acceder a la atención sanitaria no se conocen bien. 
La hipótesis inicial de este proyecto es que es que el acceso al cuidado de la leishmaniasis en África 
sigue siendo inadecuado. Los objetivos generales de esta tesis son mejorar el conocimiento 
sobre el acceso a la atención de los casos de leishmaniasis en África, documentando la 
disponibilidad, la asequibilidad y la accesibilidad de los servicios sanitarios, explorar nuevas 
formas de mejorar dicha atención y formular recomendaciones de políticas de acceso al cuidado 
de la leishmaniasis en África oriental. Los tres objetivos específicos son: actualizar los datos sobre 
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carga de enfermedad así como estudiar los problemas de acceso tanto a nivel de I+D como sobre 
el terreno.  
LOS MÉTODOS 
Cuatro metodologías distintas fueron usadas en esta tesis. En primer lugar usamos revisiones 
sistemáticas sobre la carga de enfermedad de leishmaniasis cutánea en África subsahariana y el 
impacto económico de la leishmaniasis junto a un análisis de situación del acceso a la atención de 
la LV en Somalia. Los protocolos de las revisiones sistemáticas se publicaron y registraron en 
PROSPERO y siguieron las guías PRISMA. 
Para estudiar los problemas de acceso a nivel de I+D realizamos un estudio de situación para 
evaluar si las iniciativas conjuntas entre el sector público y el privado son una solución para hacer 
frente a las enfermedades tropicales desatendidas. Realizamos un estudio de caso sobre la 
miltefosina, el único fármaco oral para VL, para analizar sus problemas de acceso posteriores a su 
comercialización. Para estudiar los problemas de acceso sobre el terreno diseñamos estudios de 
investigación cualitativa para responder a las siguientes preguntas: a) ¿Cuáles fueron las barreras 
de acceso a nivel de servicios de salud y de la cadena de suministro? Y b) ¿Cuáles son las barreras 
a nivel comunitario? Se realizaron una serie de entrevistas en profundidad con las principales 
actores a nivel mundial y nacional en Etiopía, Kenia, Somalia, Sudán del Sur, Sudán y Uganda, así 




• Atención sanitaria de la leishmaniasis visceral en Somalia 
Somalia ha sufrido un conflicto prolongado desde 1991 y se reportan casos de LV en focos 
endémicos en el sur del país. Revisamos los datos sobre la epidemiología de la LV en Somalia y 
evaluamos las opciones de control en el contexto del sistema de salud de este “estado frágil”. La 
única opción viable para el control de la LV es el diagnóstico y el tratamiento de los casos que 
actualmente asumen en su mayoría organizaciones no gubernamentales. La disponibilidad de 
atención médica de la LV en Somalia es limitada, tanto en cobertura como en calidad. Los 
problemas de seguridad siguen siendo un obstáculo para acceder a los pacientes con LV en las 
áreas endémicas, y el verdadero número de casos de LV sigue siendo desconocido. Se necesitan 
enfoques innovadores para asegurar la atención médica de los casos de LV, adaptados al contexto 
somalí. Las herramientas existentes para el control de la LV deben implementarse en zonas 
endémicas, incluyendo zonas donde los conflictos armados persisten. 
 
• Leishmaniasis cutánea en el África subsahariana 
Revisamos la epidemiología de la LC en África subsahariana. La revisión de 54 artículos reveló que 
13 de los 48 países de África subsahariana han reportado LC. Históricamente, la LC ha estado 
presente durante décadas en África occidental y oriental, pero desafortunadamente, los datos son 
escasos e irregulares. Todos los estudios revisados fueron observacionales: 29 fueron series de 
casos descriptivos (un total de 13,257 casos) y 24 siguieron un diseño transversal. Solo el 22% de 
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los estudios se realizaron post-2000. Existe una gran variabilidad en las metodologías aplicadas, 
lo que conlleva dificultades para comparar o combinar datos. La prevalencia de LC en el ámbito 
hospitalario entre los casos sospechosos osciló entre 0,1 y 14,2%. A nivel comunitario, la 
prevalencia de LC varió ampliamente entre los estudios. Se produjeron brotes de miles de casos 
en Etiopía, Ghana y Sudán. El polimorfismo de la LC en personas infectadas por el VIH es un motivo 
de preocupación para la gestión de estos casos. No hay suficientes estudios para estimar la carga 
de enfermedad y se desconocen datos críticos como la prevalencia e incidencia de LC en zonas 
endémicas, los factores de riesgo asociados a la enfermedad y el coste socioeconómico de esta. Es 
fundamental mejorar el conocimiento fragmentado de la LC y realizar mejores estudios de es esta 
enfermedad en el África subsahariana. 
  
• Impacto económico de la leishmaniasis en países endémicos 
Llevamos a cabo una revisión sistemática de los estudios sobre el costo de la leishmaniasis en 
diferentes zonas endémicas (Asia, África y América Latina) y las consecuencias para los hogares 
afectados. A pesar de la provisión gratuita de diagnósticos y tratamiento, el costo de la LV es una 
barrera crítica para acceder a la atención sanitaria en diferentes entornos, debido a los costos 
directos e indirectos asociados a la enfermedad. Los estudios publicados estiman que los hogares 
con un caso de LV gastaron entre el 11 y el 57% de los ingresos anuales en gastos relacionados con 
la enfermedad. La LV conduce a “gastos catastróficos”, pobreza continua y endeudamiento a largo 
plazo. Aunque el costo de la enfermedad está disminuyendo debido a regímenes de tratamiento 
más cortos, la situación sigue siendo difícil en África. La mejora de las herramientas de control es 
crítica. Existe la necesidad de actualizar las estimaciones de costos para desarrillar políticas de 
salud que reduzcan las barreras financieras a la atención médica de la leishmaniasis, 
especialmente en la búsqueda de la cobertura sanitaria universal. 
 
• ¿Por qué la miltefosina, un medicamento que salva vidas, no está disponible para los 
pacientes que más lo necesitan? 
La miltefosina, la única droga oral aprobada para el tratamiento de la leishmaniasis, se considera 
una historia exitosa de I+D del modelo de asociación público-privada (PPP por sus siglas en 
inglés). La miltefosina es un medicamento contra el cáncer que demostró su eficacia contra la 
leishmaniasis en la década de 1990. El desarrollo la miltefosina demostró que el modelo PPP era 
viable para promover la I+D en las NTD. En su momento, la miltefosina constituía un tratamiento 
innovador. Sin embargo, el acceso a la miltefosina después de su comercialización sigue siendo 
limitado. La baja disponibilidad y la asequibilidad han sido problemas a nivel mundial. El acuerdo 
inicial que incluía el acceso de este medicamento a través de la sanidad pública en los países 
endémicos no se cumple en la actualidad. Por ejemplo, las roturas de stock ocurren de forma 
recurrente debido a cadenas de suministro ineficientes y el uso de un producto de baja calidad 
llevó a un alto número de fallos terapéuticos e incluso muertes de pacientes. En esta tesis 
argumentamos que el desarrollo de productos para NTD debe asegurar el registro del producto y 
el acceso de este por parte de las poblaciones afectadas. El (los) mecanismo(s) para hacer cumplir 
los acuerdos que aseguran el acceso de estos productos deben mejorar, y los incentivos de I+D 
para NTD - como el vale de revisión de prioridad de la FDA - deben revisarse. Las estrategias para 
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asegurar el acceso a un medicamento para el NTD deben abordar la asequibilidad y la 
disponibilidad. 
• Barreras al acceso a la atención médica de la leishmaniasis en Gadarif, Sudán 
Realizamos 24 entrevistas en profundidad (IDI por sus siglas en inglés) y 29 discusiones de grupos 
focales (FGD por sus siglas en inglés), con un total de 191 participantes para explorar las barreras 
al acceso a la atención médica de la leishmaniasis visceral en el sur de Gadarif, Sudán. Los 
resultados del estudio describen la multitud de dificultades que enfrentan las personas cuando 
buscan atención médica para esta enfermedad e ilustran las dificultades para el manejo de la LV 
en el contexto rural de Sudán. Las diversas barreras, según lo vivido y narrado por los 
participantes del estudio, se clasifican en seis temas: conceptos erróneos, dificultades para 
obtener un diagnóstico correcto, la calidad de la atención médica, el coste de acceder a la atención 
sanitaria, las desigualdades de género y la falta de medidas de control de la LV. El acceso a la 
atención médica es siempre un fenómeno multidimensional relacionado estrechamente con el 
comportamiento a la hora de buscar servicios de salud de la población. En esta región, el 
conocimiento de la enfermedad y la búsqueda de atención sanitaria están determinadas por la 
pobreza y otros problemas estructurales en un entorno donde los recursos son extremadamente 
limitados. 
  
• Las barreras a nivel mundial y nacional para el suministro efectivo de herramientas 
para diagnosticar y tratar la leishmaniasis en África oriental : un estudio cualitativo 
El continuo suministro de herramientas para el diagnóstico y tratamiento de la leishmaniasis es 
imperativo para asegurar la asistencia médica en zonas endémicas. En el terreno la realidad es 
diferente: las empresas que aseguren productos de calidad son limitadas, el proceso de 
adquisición es largo y complejo, y hay una escasez de centros de salud que ofrezcan atención 
médica adecuada. Asegurar una cadena de suministro confiable para LV ha sido un desafío 
crónico. Desde la perspectiva de las organizaciones implicadas en el control de la LV, las barreras 
prevalecen a lo largo de la cadena de suministro (producción, adquisición y distribución de 
diagnósticos y medicamentos) y a nivel de los sistemas de salud (financiación, reglamentación y 
coordinación). Los resultados de nuestro estudio indican que a pesar de las diferencias entre 
países, se requieren esfuerzos coordinados para implementar políticas conjuntas. La coordinación 
regional y el liderazgo global son vitales. Las empresas que producen productos para el control de 
la LV deben entender las necesidades de los sistemas de salud públicos en términos de precio y 
disponibilidad en los países endémicos. El hecho que los productos médicos para la leishmaniasis 
sean adquiridos exclusivamente por el sector público y organizaciones sin fines de lucro hace que 
estrategias como compras agrupadas o conjuntas sean opciones atractivas para asegurar el 
suministro de herramientas. Pero estas iniciativas están comprometidas por la falta de 
financiamiento y compromiso a largo plazo. En los últimos años se han producido donaciones de 
medicamentos para la leishmaniasis pero estas no sustituyen la necesidad de asegurar un acceso 
sostenible impulsado por los países endémicos. Disponibilidad y distribución de diagnósticos 
para la leishmaniasis en estos países siguen sin estar resueltos.  
  
  
     
xi RESUMEN 
DISCUSIÓN GENERAL Y CONCLUSIÓN 
Asegurar que todas las personas que sufren de leishmaniasis tengan acceso rápido a un 
tratamiento efectivo sigue siendo un desafío para los sistemas de salud en países endémicos. Los 
trabajos en esta tesis proporcionan información sobre la complejidad del acceso a la atención 
medica de los casos de leishmaniasis en África, que van desde la falta de información sobre la carga 
de enfermedad, las barreras en I+D y los problemas a nivel de los sistemas de salud y las 
comunidades en zonas endémicas. El acceso a la atención médica, la estrategia de control principal 
de esta enfermedad en África, debe tener en cuenta las barreras de acceso descritas en esta 
tesis. Los programas de acceso operan dentro de sistemas y contextos de salud complejos; por lo 
tanto, cualquier estrategia aislada puede no siempre o inmediatamente traducirse en un mejor 
acceso para el paciente. El marco o estrategia para mejorar o asegurar la disponibilidad 
de atención médica para la leishmaniasis en África propuesta en esta tesis puede usarse para guiar 
futuras intervenciones.  
Los esfuerzos actuales para controlar la leishmaniasis en África oriental deben ocuparse primero 
y principalmente del acceso a la atención médica, que lamentablemente sigue siendo 
inadecuada. Las áreas afectadas por conflictos requieren estrategias innovadoras. El desarrollo de 
mejores herramientas de diagnóstico y tratamiento es crucial, pero también asegurar que estas 
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A kala-azar patient rests at a Médecins Sans Frontières hospital in Lankien, South Sudan, 2015  










1. GENERAL INTRODUCTION 
 Leishmaniasis is the common denominator for a group of neglected, stigmatising, tropical 
diseases caused by an obligate protozoan parasite - Leishmania sp.- and transmitted by sand flies. 
They either have cutaneous, mucocutaneous or visceral manifestations and disproportionately 
affect the poorest of the poor with little or no access to care. Visceral leishmaniasis (VL), also 
known as kala-azar, is a slowly progressive systemic infection that is life-threatening, and 
represent the leading focus of this thesis. The eastern Africa region reported the highest VL 
burden in the world in 20161, with 30-57,000 cases reported annually2, though the paucity of data 
from conflict-affected countries like Somalia may contribute to inaccurate disease burden 
estimates. Underestimation of the actual disease burden is thus likely. The geographic distribution 
of VL is generally limited to well-identified foci within endemic countries, but it can also suddenly 
emerge in new areas, sometimes leading to deadly epidemics. In Europe, VL has (re)emerged as 
an opportunistic infection for the immunosuppressed people, including those infected by Human 
Immuno-deficiency Virus (HIV).3–5 Contextual elements such as social unrest, drought and famine, 
conflicts leading to population movement, and weak or poorly functioning health systems have 
further hampered control measures6.  
 VL patients in the eastern Africa region face extreme challenges to access effective, quality-
assured diagnostic and treatment services for their ailment. The rK39 rapid diagnostic test (RDT) 
introduction has allowed easier diagnosis at peripheral health centres, but its sensitivity is sub-
optimal in Africa7,8. The medicines used to treat leishmaniasis are problematic in regards to safety, 
resistance, cost and varied effectiveness9. Pentavalent antimonials (sodium stibogluconate or SSG 
and meglumine antimoniate) has been the mainstay treatment since the 1940s, and together with 
an old antibiotic  ̶ paromomycin(PM)  ̶ comprised two key medicines. Currently, a 17-day 
combination of SSG/PM is the first-line recommended regimen to treat VL in the region10. Though 
this combination is shorter than the previously recommended 30 days SSG monotherapy, it still 
requires prolonged hospitalisation and painful double injections. Conventional amphotericin B is 
an alternative despite its renal toxicity, while its liposomal form (AmBisome®) unfortunately is 
not as effective in eastern Africa as it is in other regions of the world. The only oral medicine, 
miltefosine (MF) is only used compassionately, especially for VL/HIV co-infection11,12. Better, 
more appropriate drugs are needed, but the required R&D is lagging behind, for the same reasons 
as for other neglected tropical diseases (NTD)13 : little interest from industry because of the non-
viable market and little interest from the public sector as NTDs are considered minor issues in the 
face of competing for health priorities. Public-private partnerships have been proposed as a way 
out of this conundrum, along with other ‘push and pull’ mechanisms14,15. 
 In eastern Africa, problems with leishmaniasis care are currently rampant from source to 
the stream. The availability of the drugs mentioned above that are essential for clinical care is 
compromised by the inability of patients to pay, by a shrinking market volume due to the 
downward trend in VL incidence in South Asia, and by the lack of competition as most drugs are 
produced by virtually a single manufacturer16. Moreover, the availability and affordability of 
quality-assured leishmanial medicines in endemic countries are also hampered by weak supply 
chains and pharmaceutical management17. Even where diagnosis and treatment are provided for 
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free at public health facilities, VL patients and families still have to pay out-of-pocket for other 
non-medical costs, such as transport or food for caretakers for prolonged periods18,19. The cost to 
seek care results in catastrophic health expenditure for the family and poses as one of the main 
barriers to accessing quality treatment for leishmaniasis in Africa. Other barriers perceived by the 
community may be linked to socio-cultural factors and health-seeking behaviour in a particular 
context. If unaddressed, these barriers lead to delay in seeking treatment which worsens the 
clinical prognosis for the patient but also foster continued transmission20. In eastern Africa, these 
barriers are still poorly understood.  
 Ensuring that all individuals suffering from leishmaniasis have prompt access to life-
saving effective diagnosis and treatment remains a challenge for resource-constrained health 
systems. The lack of R&D for leishmaniasis further exacerbates this sub-optimal access. VL care in 
eastern Africa disproportionately lags behind compared to the standards of care in southern 
Europe and other regions in the world. Against this backdrop, I conducted this research project 
focusing on the access continuum for leishmaniasis in Africa. Investigating ‘access’ to an NTD 
requires a broad horizon encompassing the dimensions of availability, affordability, quality and 
adoption. The following paragraphs will provide an overview of the state of knowledge that 
informed my research questions at the start of this thesis project.  
 
2. LEISHMANIASIS 
 Apart from being a poverty-related disease, leishmaniasis is characterised by both 
diversity and complexity21. More than 20 species of Leishmania genus can cause the disease, with 
close to 100 medically important species of sand flies (genus Phlebotomus and Lutzomya) as 
vectors (Figure 1). The parasite reservoir can be human (in anthroponotic forms of the disease) 
or animal (zoonotic), depending on species. Leishmania parasites are transmitted through the 
bites of infected female phlebotomine sand flies, which feed on blood to produce eggs. The 
epidemiology of leishmaniasis depends on the characteristics of the parasite and sand fly species, 
the local ecological characteristics of the transmission sites, current and past exposure of the 
human population to the parasite, and human behaviour. 
 The leishmaniasis is endemic in many tropical and subtropical regions in large areas of 
South Asia, the Middle East and North Africa (MENA), eastern Africa, the Mediterranean basin and 
Latin America. The World Health Assembly enshrined the importance of leishmaniasis control in 
resolution WHA60.13 in 200722. Approximately 1.7 billion people, or one-quarter of the world's 
population, live in areas where they are at potential risk of leishmaniasis23. Leishmaniasis rank as 
a leading NTD in the 2017 Global Burden of Disease study, in terms of morbidity and mortality, 
causing an estimated 774 (range 199 to 2720) thousand DALYs (Disability Adjusted Life Years), 







Figure 1. The life cycle of leishmaniasis 
Source: Reithinger et al., The Lancet Infectious Diseases, 2007; 7(9): 581-596 doi: 10.1016/S1473-
3099(07)70209-82007; reproduced with permission from Elsevier  
  
 The most frequent clinical form of leishmaniasis is cutaneous (CL), estimated at 0,7 to 1,2 
million cases per year with up to 10% of cases progress to severe manifestations (disseminated, 
diffuse or mucocutaneous forms)25. The CL skin lesions, typically appear as ulcers on exposed 
parts of the body, may leave life-long scars and serious disability or stigma. Forced migration and 
lack of control measures were drivers of increased CL incidence in recent years, for example in 
Iraq, Lebanon, Pakistan and Syria26. More than 95% of global CL cases in 2017 are reported from 
Afghanistan, Algeria, Brazil, Colombia, Iran (Islamic Republic of), Iraq, and the Syrian Arab 
Republic. Mucocutaneous leishmaniasis (MCL) is the form with partial or total destruction of 
mucous membranes of the nose, mouth and throat. Over 90% of mucocutaneous leishmaniasis 
cases occur in Bolivia (the Plurinational State of), Brazil, Ethiopia and Peru. VL is fatal without 
adequate treatment and may have sequelae in the form of Post Kala-azar Dermal Leishmaniasis 
(PKDL). PKDL appears as macular, maculopapular or nodular skin rash and may self-heal as 
observed in Sudan27, though its importance as driver of transmission has gained importance in 
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GLOBAL EPIDEMIOLOGY AND CONTROL OF VISCERAL LEISHMANIASIS  
 VL or kala-azar is a systemic disease characterised by persistent irregular fever and 
hepatosplenomegaly. It is caused by the Leishmania donovani in Asia and Africa, and L. infantum 
in northern Africa, the Mediterranean region and Brazil. Previous VL estimates, based on 2008 
surveillance data reported to WHO, were 200,000-400,000 cases with 20,000-40,000 deaths 
annually2. Based on 2014 data, the current estimate is between 50,000-90,000 cases per year, 
distributed in 75 countries (Figure 2)1,22. Currently, 78% of global VL cases occur in four 
countries: Brazil, India, South Sudan, and Sudan. Together with Kenya, Ethiopia, and Somalia, 
these seven countries represent 90% of VL cases worldwide. 
 
Figure 2. Status of endemicity of visceral leishmaniasis worldwide, 2016 
Source: WHO, 2018 available at https://www.who.int/wer/2018/wer9340/en/ 
 
 The bite of female sand flies, either of the Phlebotomus spp. (in the Old World) or the 
Lutzomyia spp. (in the New World), maintain VL transmission, either with humans as the only 
reservoir (anthroponotic transmission), or involving animals (zoonotic transmission). Domestic 
dogs, rodents, sloths, and opossums are amongst a long list of mammals that are either 
incriminated or suspected reservoir hosts30. Prevention and control strategies recommended by 
WHO vary according to the region based on transmission dynamics and available evidence. These 
include diagnosis and treatment, vector control (using chemical molecules or through 
environmental management), control of reservoir hosts, along with surveillance and social 
mobilisation. To this date, the quest to develop leishmaniasis vaccine still continues.  
 In 2005, the governments of Bangladesh, India and Nepal signed a Memorandum of 
Understanding to eliminate VL from the region, and this elimination initiative has since drawn 
considerable support from the international community31,32. In the Indian subcontinent, certain 
epidemiological features render elimination technically possible, i.e. humans are the only 





insecticides. Along with the availability of improved control tools (the rK39 RDTs and oral 
miltefosine) and the level of political commitment, WHO considered it operationally feasible to 
reduce the burden of VL to a level at which it is no longer a public health problem (defined as 
incidence of fewer than 1/10,000 cases per sub-district) by 2015. This deadline has since been 
extended to 2020. The incidence has indeed notably declined since 2005, and Nepal and 
Bangladesh both reached the target. However, the natural cyclical epidemiological pattern might 
contribute to the rapidly declining incidence in this region25.   
 The VL elimination remains unfeasible in eastern Africa, as the endemic region is affected 
by civil unrest, the diagnostic and treatment tools are suboptimal, and the epidemiological 
parameters are different, with multiple vectors and most likely, an animal reservoir33,34. In eastern 
Africa, the VL burden is steady and even increasing, whereby under-reporting of cases remains a 
continued concern. When control programmes rely on passive case detection only, as they do in 
eastern Africa, there is a significant proportion of leishmaniasis patients who remain undetected 
and untreated. Several major VL epidemics of VL have been building up in the past, driven by 
population displacement due to conflicts, such as in Somalia and South Sudan35,36. A high co-
infection rate with HIV, up to 20% in Ethiopia, has also made control efforts more challenging37.  
 
CLINICAL MANIFESTATION, DIAGNOSTICS AND TREATMENT STRATEGIES 
 A Leishmania infection does not always lead to clinical disease as asymptomatic infections 
outnumber the clinical cases. When symptoms occur, the onset can be acute or insidious; the 
incubation period of VL varies between 2 weeks and eight months. Suspected cases of VL typically 
have prolonged fever (of ≥2 weeks), spleen enlargement and weight loss, along with 
pancytopenia, hepatomegaly and hypergammaglobulinemia. If left untreated, the disease 
progresses with time, causing debilitation, bleeding, susceptibility to secondary infection and, 
eventually, death.  
 Early and accurate laboratory diagnosis is essential before initiating treatment as the 
clinical features of VL are non-specific and may resemble those of several other diseases including 
malaria or other conditions (infectious and not-infectious). Furthermore, available drugs are 
potentially toxic and in general require hospitalisation. On the other hand, undiagnosed cases 
would result in death without timely treatment and would maintain transmission. Correctly 
diagnosing VL, therefore, is essential for case management of VL. 
 Parasitological diagnosis remains the gold standard in VL diagnosis, because of its high 
specificity. The microscopic examination of Giemsa-stained smears could be done from spleen 
(highest sensitivity: >90%), bone marrow (sensitivity 50-70%) and lymph node. Spleen aspiration 
is invasive and carries a risk of bleeding, estimated at 1/1000 procedures38. Serology-based tests 
are available, such as ELISA, immunofluorescence and western blot, but they still require well-
equipped laboratory and skilled personnel and therefore their use is limited. Based on this gap, 
two serological tests have been specifically developed for field use: the direct agglutination test 
(DAT) based on the freeze-dried antigen and the rK39 immunochromatographic test (generally 
referred to as the ‘rK39 RDT’). The latter offers more advantages as RDTs are simpler to perform 
and provide result faster, making them convenient for use at peripheral health centres. However, 
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the rK39-RDTs’ diagnostic accuracy varies between regions, with excellent sensitivity in the 
Indian subcontinent (97%, 95% CI 90-100) but only 87% (95%CI 75-93) in east Africa39. Another 
limitation of antibody tests is their inability to differentiate past and current cases. Several 
antigen-based tests are being developed to overcome this, though their use is still limited. This 
includes a latex agglutination test (sensitivity 64% [95% CI 41-86]) and IgG1 based-tests40. More 
sophisticated techniques such as molecular diagnostics are expensive and rarely available outside 
specialised centres. The health system level where diagnostic tools are deployed or made 
available have to be considered, for example between primary centres, district hospitals and other 
tertiary level.  
 All medicines for VL were initially developed for other indications, except the ancient 
compound antimony that has been widely used in the early modern medicine (see Table 1). 
Significant advances have been made in the past decades, owing mainly to the efforts of non-profit 
organisations, including WHO's Special Program for Research and Training in Tropical Diseases 
(TDR), or public-private partnership entities such as Drugs for Neglected Diseases initiative 
(DNDi), Institute for One World Health, and Non-Governmental Organisations (NGOs) such as 
Médecins Sans Frontières (MSF), and others. Treatment guidelines are not uniform because of 
different levels of efficacy according to regions, and each of the treatment options has significant 
limitations41. Combination treatments with existing drugs have also been advocated to optimise 
the efficacy and safety of treatment, reduce costs and hospitalisation time, and to prevent 
resistance42. In the Indian subcontinent, the combination of MF+PM is included as second-line 
treatment, while other combinations such as LAMB+MF and LAMB+PM have also been evaluated 


















Dosing* 20 mg/kg/day; 
30 days 
1 mg/kg on 
alternate days 
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within the region 
IV-intravenous; IM-intramuscular 
* Note that monotherapy is no longer recommended as first-line treatment (except LAMB for India, Nepal and 
Bangladesh), and the dosage may differ when used in combination therapy. See Table 3. $ when used as combination 
treatment with antimonials for 17 days in eastern Africa.
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 SSG, when used alone in eastern Africa, requires 30 days of painful daily intramuscular 
injections and may cause serious (cumulative) toxic side effects. PM, an aminoglycoside, needs to 
be administered in combination with another drug in order to optimise its use. African countries 
switched to the WHO-recommended combination regimen of 17 days SSG/PM (both 
intramuscular injections) in 2011. Miltefosine (MF), the only oral medicine, is contra-indicated 
during pregnancy, and is susceptible to develop resistance with a single point mutation due to its 
long half-life. Used in monotherapy, its treatment duration is 28 days and requires strict 
adherence, with contraceptive provision for at least three months post-treatment46. Conventional 
Amphotericin-B deoxycholate is a cumbersome treatment that needs to be given in slow 
intravenous (IV) infusions daily or every other day for 15 doses. Careful hydration and potassium 
intake of patients are needed to avoid renal toxicity and hypokalaemia. Its liposomal form, 
LAMB/AmBisome® is administered intravenously and must be stored and transported in a 
manner that ensures the vial is not exposed to temperature over 25˚C. Its current cost remains an 
important barrier to treatment47 though the manufacturer has previously set an access price, and 
later agreed to donate the drugs for VL treatment in several countries since 2011, facilitated by 
WHO48,49. LAMB has excellent efficacy and safety profile, either when used alone or in combination 
with an oral drug. However, LAMB in Africa is less effective and requires higher doses compared 
to the Indian subcontinent50. Currently, it is used in treatment failures, severely ill patients, those 
co-infected with HIV, pregnant women and those under two and over 45 years of age51–53 . The 
pursuit of finding the most effective regimen is still ongoing, and particularly for Africa, the quest 
is longer and admittedly more difficult. 
 
3. LEISHMANIASIS IN AFRICA 
EPIDEMIOLOGY AND BURDEN OF LEISHMANIASIS IN EASTERN AFRICA  
 With the declining incidence in the Indian subcontinent, eastern Africa is now the region 
with the highest VL burden in the world. Sudan is the most affected country, followed by South 
Sudan, Ethiopia, Somalia, Kenya, and Uganda1. Eritrea and Djibouti have reported leishmaniasis 
cases in the past. This region showed an increasing trend in the proportion of the global burden 
of VL, from 9602 cases (40%) in 2015 to 11,215 cases (50%) in 20161, and believed to have 6-10 
years cyclical patterns (Figure 3). Historically, leishmaniasis has been reported since the early 
20th century by medical officers during colonial times 54,55. It is difficult to assess the real burden 
of VL56, but a cross-sectional survey in Gadarif in eastern Sudan revealed an overall incidence of 
VL in 2010 of 7.0/1000 persons per year. 12.5% of the population reported a past VL treatment 
episode57. A considerable variation between villages or clusters has been reported, while evidence 
on risk factors are mixed58–62.  
 
                                                             
 
1 South Sudan gained their independence from Sudan in July 2011. In the older literature, Sudan and South Sudan were 
reported as one country. Sudan and Somalia belong to WHO Eastern Mediterranean Region (EMRO) while Ethiopia, 






Figure 3. Reported cases of visceral leishmaniasis in the African region (1998-2015). Source: WHO 
 Transmission is considered as largely anthroponotic in this region21, and the role of an 
animal reservoir is unclear despite the discovery of parasite DNA in dogs and rodents63,64. The 
known principal vectors of L. donovani are Phlebotomus orientalis, Ph. martini and Ph. celiae65. 
P. orientalis occupy a distinct habitat characterised by the presence of chromic vertisols (black 
cotton soils) that form large cracks during the dry season, and are covered with Balanites 
aegyptiaca and Acacia seyal trees; while Ph. martini and Ph. celiae are associated with termite 
mounds. The latter can be found in foci in Somalia, Kenya and Ethiopia. VL spreads over a broad 
belt from the Atbara river in the north-east along the Sudanese-Ethiopian border to the south of 
the Sobat river and Nassir and Malakal and extending west across the White Nile (see Figure 4).  
 
Figure 4. Distribution of visceral leishmaniasis (VL) cases in East Africa.  
A. This satellite image is taken from Google Maps; B. The distribution of VL for each region or state within 
East African countries. The largest affected area in terms of number of cases is the eastern region of Sudan 
and neighbouring Ethiopia (Area 1), followed by South Sudan (Area 2), Darfur and Western Sudan (Area 3), 
and Somalia (Area 4), and Kenya with North-East Uganda (Area 5) Source (with permission): Saleem et al. 
Parasites & Vectors2016, 9:460DOI: 10.1186/s13071-016-1743-7 
 
26 Access to leishmaniasis carein Africa 
 The epidemiology of VL in eastern Africa is particularly driven by its context. The violent 
conflicts of the past 40 years have induced massive movements of susceptible or infected 
populations into VL-endemic or non-endemic areas, respectively, triggering major epidemics. 
Sustained droughts have led to widespread malnutrition and famine, known to be risk factors for 
VL. Conflict and drought probably caused the most massive VL epidemic ever recorded, during the 
1980s in southern Sudan, where VL killed an estimated one-third of the 280,000 population of a 
district3. An outbreak starting in 2009 in Upper Nile, Jonglei, Unity and Eastern Equatoria 
provinces of South Sudan caused over 32,000 cases36,66. Following a clash in December 2013, 
another outbreak occurred in 2014 with close to 8000 cases reported4, and to date the disease 
trends are unpredictable. Refugees fleeing the conflict in Somalia caused an outbreak in Dadaab 
refugee camp in Kenya. The ensuing investigation established the existence of a VL endemic area 
in Bakool region in Somalia, where they came from67. Another epidemic in the non-endemic area 
of Libo Kemkem, Ethiopia was confirmed to be VL, though initially thought to be caused by drug-
resistant malaria68,69. Partly attributed to seasonal population movement, i.e. the labour migration 
from highland to the lowland to work in agricultural farms, this phenomenon also reveal another 
challenge of increasing VL/HIV co-infection37.  
 One element affecting leishmaniasis is the socio-economic aspects, either at risk of 
exposure and access to medicines and diagnostics. Socio-economic burden of VL, its impact and 
consequences, is well described in India, Nepal and Bangladesh through cost of illness studies. 
These studies, when conducted well, provide insights to inform policymakers on economic burden 
from the perspective of individual/household or health care provider or both (societal 
perspective). From eastern Africa, there is only one study by Meheus, et al. (2013) that reported 
the economic burden of VL with data from Gadarif, the epicentre of VL in Sudan70. The median 
total cost for one VL episode was estimated to be US$450, of which 53% is borne by the 
households (40% of the annual household income. More than 75% of households incurred 
catastrophic out-of-pocket expenditures. Further evidence is clearly needed.  
 
CUTANEOUS LEISHMANIASIS IN AFRICA 
 CL is present in 67 countries in the Old World (Europe, Africa, Middle East, central Asia 
and the Indian subcontinent). The causative agents of CL in Africa are dermotropic L. major, L. 
aethiopica, L. tropica, and, rarely, L. donovani. CL in Africa has complex transmission cycles 
involving animal reservoir host (e.g. hyraxes) and sand fly vectors (P. longipes and P. pedifer). 
Environmental changes such as agricultural, irrigation, migration and urbanisation may increase 
the risk of exposure for humans. When susceptible populations become exposed, it may result in 
noticeable epidemics, such as in Burkina Faso, Ghana and new pockets in Ethiopia. In Sudan, an 
epidemic affecting >10,000 people occurred in 1991 in Tuti island, near Khartoum. Movement of 
a non-immune population aided by high vector abundance following heavy rains was thought to 






Figure 5 Status of endemicity of cutaneous leishmaniasis worldwide, 2016 
Source: WHO, 2018 . Available at https://www.who.int/wer/2018/wer9340/en/ 
  
 There is a wide variety of CL clinical presentations, depending on different factors such as 
parasite species, transmission cycle, immunological status or genetic predisposition. In general, 
CL refers to ulcerative skin lesion(s), which can be developing at the site of the sand fly bite 
(localised) or multiple non-ulcerative nodules (diffuse). CL may vary in severity (e.g., in lesion 
size), clinical appearance (e.g., open ulcer versus flat plaques versus wart-like lesions), and 
duration (e.g., in time of evolution or in time to spontaneous cure). Most L. major lesions self-heals 
in several months. Some complicated forms can be extremely disfiguring or debilitating, such as 
those caused by L. aethiopica. CL lesion may mimic that of other skin conditions, such as 
staphylococcal or streptococcal infection, mycobacterial ulcer, leprosy, fungal infection, cancer, 
sarcoidosis, varicose ulcers, or tropical ulcer. Diagnosis is often made clinically and treatment 
options – using the same medicines as for VL  ̶ are mostly prolonged and with low cure rate. 
Depending on the severity of the cases, treatment can be given topically (including 
thermotherapy), intralesional injections or systemic therapy but the evidence is lacking71. 
 Although rarely fatal, CL can cause substantial suffering because of the related stigma and 
the disfiguring scars it leaves in a number of cases. Accurate disease burden is challenging since 
misdiagnosis is common and there are no standard reporting guidelines. There is a major 
knowledge gap in terms of the magnitude of the problem, in particular for sub-Saharan Africa. The 
lack of epidemiological burden and distribution makes it difficult to advocate for control activities 
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EXISTING INTERVENTIONS TO CONTROL LEISHMANIASIS IN AFRICA 
 Vector control strategies for VL include insecticide spraying, use of insecticide-treated 
materials, and environmental management65. Unfortunately, not much evidence exists about their 
effectiveness in eastern Africa, and they are not widely used. The only evidence on bed-nets was 
a retrospective study by MSF in Sudan following community distribution of insecticide-treated 
nets (ITN) in 1999-2001, which reported a 59% reduction of vector density72.  
 In the absence of vaccines and effective vector control strategies, case detection and 
treatment remain the principal VL control approach in this region. In eastern Africa, major 
knowledge gaps remain and such concerted efforts to tackle VL seem utopic. The public health 
importance of VL is further underestimated, partly because of the limited knowledge of the 
disease burden to inform policy decisions. 
 Nevertheless, there have been several signs of progress. With increased attention to NTDs 
from stakeholders and support from external partners, control of leishmaniasis was established 
in each leishmaniasis endemic countries, along with publication and dissemination of national 
leishmaniasis guidelines (Table 2). Leishmaniasis is a notifiable disease in Sudan, South Sudan 
and Ethiopia, but not in Somalia, Kenya, nor Uganda. Surveillance type also differs, with an 








Table 2 Overview of visceral leishmaniasis status and control in eastern Africa 
  Ethiopia Kenya Somalia South Sudan Sudan Uganda 
Endemic areas 6 out of 9 regions 
6 out of 47 
counties 
14 out of 90 
districts 
28 out of 86 
counties 
27 out of 187 
localities (in 12 
states) 
52 out of 146 
counties 
Total Population 99,290,750 46,050,302 10,787,104 12,339,802 40,234,882 39,032,883 
Poverty headcount ratio at $1.90 a day (2011 PPP) (% of 
population 
NA NA NA NA NA 34,6 (2012) 
Health expenditure per capita (current US$) 26,6 77,7 NA 30 129,8 41 
Out-of-pocket health expenditure (% of total expenditure on 
health) 
32,3 26,1 NA 54,2 75,5 52,3 
Population at risk in 2015A 3,168,835 3,268,626 2,337,787 2,034,944 8,696,636 No data 
VL cases per year (estimate)B 3700-7400 610-1200 1400-2700 15,700-30,300 7,400-14,200 350-520 
VL cases reported in 2016C 1490 954 858 3541 3894 31 
National VL guidelines (last update)D Yes (2013) Yes (2017) Yes (2012) Yes (2011) Yes (2016) Yes (2019) 
National leishmaniasis control programme Yes, since 2006 Yes, since 2012 Not available Not available Yes, since 2012 
Not standing 
alone 









44 hospitals 1 Hospital 
Treatment provided for free in public sectorG Yes Yes Yes Yes Yes Yes 
 
A Data from 2015 WHO Country Profile on leishmaniasis, available at http://www.who.int/neglected_diseases/news/New_leishmaniasis_country_profiles_based_on_routine_surveillanc/en/  
B Estimate from Alvar et al., 2012 based on WHO data since 2008. 
C Data from WHO Global Surveillance of Leishmaniasis, available at http://apps.who.int/gho/data/node.main.NTDLEISH?lang=en  
D First-line for all the countries are combination regimen of SSG/PM for 17 days 
E Ethiopia has 22 facilities, including a refugee camp in Gambella where MSF is present. (source: MSF and KalaCORE) 
F South Sudan has 38 facilities that are receiving full support (supplies, supervision and on-site mentorship) and another 8 that are receiving more indirect support (source: KalaCORE) 
G Despite official free diagnosis and treatment, patients and household still have to pay other non-medical costs, notably transport, hospitalisation, and food 
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 To avoid treating false positive, RDT should only be used for patients fulfilling a clinical 
case definition, defined by WHO as someone presenting with persistent fever (≥2 weeks) and 
splenomegaly in a VL endemic area. DAT and parasitological confirmation are only available at 
higher level health facility as they require minimum equipment and skills. Adherence to the 
diagnostic algorithm in daily practice is influenced by the availability of options and training of 
the clinicians73. The rK39 RDT is the most widely used, despite its sub-optimal accuracy 
(sensitivity 85%) in the African region39. Performance variability due to heat stability, different 
lots and brands have also been reported in the past74. Availability of RDT can also be a constraint: 
in Sudan, due to the United States' economic sanctions, importation of certain rK39 (DiaMed‐IT 
LEISH®, Bio-Rad International) was impossible and as a result, the national programme has rolled 
out another brand (Kalazar Detect™, InBios International), which has been documented to 
perform less well (suboptimal sensitivity of 67.6%18). There exist other recombinant antigens for 
RDT such as rK9, rK16, rK26 and rK2875. The latest has recently been studied in Sudan with 
satisfactory result76,77.  
 There has been a shift towards combination therapies with shorter treatment regimen as 
first-line protocol (17 days of SSG/PM instead of 30 days SSG)10. It is a fact that to treat a VL patient 
is more difficult in eastern Africa than in South Asia, where similar treatments have an efficacy of 
>95%, except for SSG, for which resistant strains have been clearly described in India78 (Table 3). 
Inter and intraregional variation have also been observed in eastern Africa; for instance, PKDL 
manifests in an estimated 40 to 50% of patients in Sudan79, but rare in areas of Kenya and 
southern Ethiopia. Lymphadenopathy is frequently found in Sudan but not in other regions. 
Medicines may demonstrate shown variable effectiveness across foci , such as the case with PM in 
eastern Africa80. These differences can partly be explained by the heterogeneity of vectors, host 
factors, and parasite across and within the region 81–83.  
 
Table 3 Treatment efficacies in South Asia and Eastern Africa* 
 
SSG – sodium stibogluconate; LAMB -liposomal amphotericin B; MF -miltefosine; PM -Paromomycin. *Adapted from 
Alves et al., 20189 
  
 Although SSG-PM combination therapy is an improvement over SSG monotherapy, a new 
therapy for VL should ideally be a safer, more efficacious, and shorter-course oral combination 
regimen. Control tools need to be suitable for implementation in the remote locations of the 
populations affected in eastern Africa. Nevertheless, there are myriad of challenges in bringing 






















South Asia 35-95 >95 ≥95 72-94 94,6 NIA NIA >97 >97 >97
Eastern Africa 93.9 85 (71-100)58 (33-100) 72 63,8 (14-96) 91 87 77 NA NA





CHALLENGES IN PROVIDING VL CARE: ACCESS AND HEALTH-SEEKING BEHAVIOUR  
 Without treatment, VL is almost always fatal. Delays in detection and treatment increase 
the risk of morbidity and mortality as well as the dissemination of disease to others. Accordingly, 
early access to VL care is imperative to improve clinical prognosis and reduce transmission via 
human reservoirs. Tragically, many individuals may fail to access VL care. Focusing on supply-side 
intervention, i.e. providing care on health service or health system does not guarantee utilisation 
by the patients, especially in the eastern Africa context. 
 Moreover, the care-seeking behaviour for VL is rarely straightforward. Many barriers exist 
between the onset of symptoms and completing, or even starting treatment. Typically, different 
health care providers need to be visited before the patients reached a VL diagnosis, with the choice 
primarily based on proximity and reputation84,85. As VL patients mostly live in remote, rural areas, 
the reach of the formal health system is limited: they arrive at the hospital (where VL care is made 
available), when the illness has become severe and with complications. Furthermore, a delay 
occurs already at individual/household level regarding the decision to seek care (if awareness is 
low), while the physical access to the health services also a determinant (Figure 6). Financial 
constraints play a role; during the rainy season, transport from rural area to the city is more 
difficult, e.g. can only be done by tractor or private rented vehicle, requiring more time and money. 
Lengthy hospitalisation period86 might hinder the perceived benefit of treatment as socio-
economic impact to the household is significant70. Previous stock-out or shortages of VL 
diagnostics and medicine might affect the expectation and perception of the care available. 
 
Figure 6 Difficult geographical accessibility in Sudan (left) and lack of transport means (South Sudan). 
(Courtesy of MSF.) 
 Even when patients do seek care, the diagnosis was not always easy, with the delay to 
reach diagnosis up to 5 weeks87. In Nepal, the time to reach the teaching hospital tertiary care 
where VL care is provided took up to two months, and in India, the median duration from illness 
to cure was up to 14 weeks84,87. Health service delay is also common, i.e. further delay before the 
diagnosis is made and treatment is started, for example, due to the unavailability of the health 
staff or diagnostic tests and medicines. 
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 Inadequate access to VL care is thus reflected in a relatively long duration between the 
onset of symptoms and the moment the patient seeks treatment, up to weeks and months. One 
study investigating accessibility of VL care in Sudan conducted 15 years ago, identified the 
following factors as access barriers: low knowledge, lack of money for treatment and transport, 
impassability of roads especially during rainy season, work priorities, severe cultural restrictions 
of women’s decision-making power and distance to the next health center88. Apart from this study, 
there is no other published information on the experience and perspective of the VL affected 
communities. 
  Another challenge of VL care provision is linked to the health system capacity, which 
varies widely and also within the country. Quality care is often hampered by high turnover of 
medical staff or bottlenecks in the pharmaceutical supply chain, including poor stock management 
(Figure 7). Several non-state actors have long been involved with VL control in the region, such 
as MSF, DNDi and more recently, KalaCORE consortium89. Availability of diagnostics and 
medicines is vital, but shortages often happen90. Lack of reliable data and difficult communication 
lead to forecasting difficulties and sub-optimal practices. The quality of diagnostics and medicines 
may not always be ensured if proper storage and transport to the health facilities are not 
guaranteed. The distribution to the peripheral health facilities is hampered by geographical or 
climate (rainy season in South Sudan, for example). Counterfeit or sub-standard drugs have been 
reported before91 .  
 
Figure 7 Leishmaniasis medicine in the field  







4. LEISHMANIASIS AS A NEGLECTED DISEASE 
NEGLECTED DISEASE, A REPACKAGING OF A GLOBAL HEALTH MOVEMENT 
 Neglected diseases, or the so-called Neglected Tropical Diseases (NTDs), refer to a diverse 
group of communicable diseases that prevail in tropical and subtropical conditions and affect 
populations living in poverty92. The critical feature of this group of diseases is the ‘neglect'; 
implying that they are concentrated in the impoverished population living in marginalised areas, 
those who are left behind by socio-economic development. There is a lack of visibility at all levels: 
community, national and international; which leads to a lack of incentives to develop medicines 
for them as the patients are too poor to pay the price. Sadly, even existing medicines may not reach 
the patients due to access issues and poor delivery system93. Neglected diseases affect neglected 
populations.          
  
 The concept of NTDs emerged in the early 2000s, almost as alternative ‘brand' or 
repackaging when most attention goes to the big three diseases (HIV, tuberculosis and malaria), 
and have continued since to generate momentum in the international community94. The NTD 
movement was not launched in vacuum but constructed within the shifting policy landscape 
driven by the Millennium Development Goals (MDG). Key WHO meetings took place in Geneva and 
Berlin in 2003, and these initiatives create an initial framework for NTDs, focusing on mass drug 
administration as the ‘rapid impact package’ for at least seven diseases94,95. Scientists or ‘scientists 
activists’ have largely led the global policy movement and create critical mass for policy and public 
actions, which led to further institutionalisation through WHO and other stakeholders such as 
London Declaration on NTDs in 2012 (Figure 8). In the latter, pharmaceutical companies, donors, 
academia, endemic countries and NGOs came together to commit to control, eliminate or eradicate 
NTDs and improve the lives of over a billion people96,97. Several multinational pharmaceutical 
companies have agreed to donate the necessary drugs to eliminate lymphatic filariasis (LF) and 
blinding trachoma and to control onchocerciasis, soil-transmitted helminths infection (STH) and 
schistosomiasis98. In May 2013, the 66th World Health Assembly passed a new resolution on 
prevention, control, elimination and eradication of NTDs, urging member states to step up their 
commitment and resources to tackle NTDs99. 
Box 1 
‘These diseases, many of which have affected humanity for millennia, affect more than 1.4 billion people. 
They sicken, disable, and disfigure, keeping people in cycles of poverty and costing developing economies 
billions of dollars every year. Until recently, NTDs saw little attention from all but a small handful of 
dedicated supporters. Bus as their impact grew clearer, more were urged into action. ‘  
     Uniting to Combat NTDs 2014 (Delivering on Promises and Driving 
Progress; The 2nd Report on Uniting to Combat NTDs 
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 Initially consisted of 17 diseases2, through WHO’s Strategic and Technical Advisory Group 
for NTDs, additional diseases have been included in the NTD portfolio3. Five broad strategies to 
tackle NTDs are preventive chemotherapy (PCT), intensified disease management (IDM), vector 
control, veterinary public health measures and through improved water and sanitation. These 
interventions are being implemented with variable intensity and resources. Mass drug 
administration is the central intervention for diseases amenable to PCT, such as soil-transmitted 
helminths and lymphatic filariasis. Drug donation programme by pharmaceutical companies has 
mainly directed towards this PCT.  
 
    
Figure 8. (left) The first WHO Road Map to Tackle NTDs; (right) Various advocacy and media attention 
for the global health partnership to tackle NTD (source: WHO and Uniting to Combat NTDs, 
https://unitingtocombatntds.org/) 
 
 Leishmaniasis, along with Buruli ulcer, Chagas, Human African Trypanosomiasis (HAT) 
and yaws, belongs to the IDM diseases for which cost-effective control tools do not exist and 
where large-scale use of existing tools is limited. These diseases also share the same 
characteristics: they are difficult to manage and costly (diagnosis, treatment), poorly understood 
burden, lack of investment in Research and Development (R&D), and people affected have poor 
or no access to health care. Intensifying disease management using existing tools basically means 
to make do with diagnostics and medicines, while at the same time advocate for rapid 
development and implementation of better control tools and to ensure the full involvement of 
                                                             
 
2Buruli ulcer, Chagas disease, Dengue/Chikungunya, Dracunculiasis, Echinococcosis, Yaws, Human African 
Trypanosomiasis, Leishmaniasis, Leprosy, Lymphatic Filariasis, Onchocerciasis, Rabies, Schistosomiasis, Soil-
transmitted Helminthiases, Taeniasis/Cysticercosis, Trachoma 
3Mycetoma or chromoblastomycosis and other deep mycoses, scabies and other ectoparasites and snakebite 





national control programmes. There has been a resolution on control of leishmaniasis in 2007 to 
encourage endemic countries to take ownership of the leishmaniasis programme. 
 
LANDSCAPING OF R&D FOR NTDS INCLUDING LEISHMANIASIS 
 At present, development of new medicines by the pharmaceutical industry is driven 
largely by future ‘return on investment’ based on intellectual property rights (patents) and market 
exclusivity. Getting a drug in the market The drugs discovery and development process and then 
getting them to the market is a long, slow haul (Figure 9). The associated failures at every stage 
make the process costly and serve as justification of the product’s final pricing100,101. Without the 
for-profit market, pharmaceutical manufacturers have no economic reasons to develop drugs for 
conditions like NTDs, which primarily affect the poor. This ‘market failure' is reflected in the rate 
of new drugs developed for infectious diseases that are mainly prevalent in developing countries. 
In 1975-1999 only 15 (1.1%) of 1393 new medicines (New Chemical Entity/NCE) were dedicated 
to tropical diseases16. Between 2000-2011, this proportion did not change and amongst the newly 
approved products for NTDs, most were new formulation or combinations of existing medicines13. 
There is a vacuum in the drug R&D for diseases of the poor and also for diseases with small market 
size, often called the ‘orphan’ or rare diseases.  
 
Figure 9 Drug discovery and development pipeline. Graph adapted from Nwaka S and Ridley R (2003). 
‘Virtual drug discovery and development for neglected diseases through public-private partnerships.’ 
Nature 2: 924  
 As maximizing profit of sales and shareholders’ value are the main incentives for 
pharmaceutical companies, developing new drugs for NTDs and rare diseases are not prioritised. 
For these conditions, market mechanisms alone were insufficient and public policy needs to 
remedy the situation16,102. Specific regulatory and economic incentives have thus been created to 
foster R&D for rare diseases in the United States, Japan, and Europe103 since the 1980s. 
Unfortunately, not all problems are solved as the access to these ‘orphan drugs’ remains 
problematic due to high cost104.  
 Similarly for NTDs, there has been a continuous advocacy for public actions to seek 
alternative approaches to R&D for NTDs. Public-Private Partnership (PPP), one type of which is 
Product Development Partnership (PDP), have emerged as one potential solution. PDPs supposed 
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to knit together the public and private sector, along with NGOs, academia, biotech companies; 
working virtually to link expertise, provide funding, technical oversight and portfolio 
management. WHO/TDR, created in 1975, has been involved in driving drug development for 
neglected diseases in PPP arrangements, encouraging others, e.g. Malaria Medicine Venture 
(MMV), DNDi, and TB Alliance, amongst others, since the early 2000s. In fact, three of 
leishmaniasis drugs (LAMB, MF and PM) were fruits of this approach (see Box 2). The success of 
PPP in this regard was a reassurance of an alternative way to a develop drug in a capital-intensive, 
market-driven context. However, whether PPPs are the real solution to tackle NTDs remains an 
open question, especially on its outcomes, policies and practice. 
  
  
 The landscape in the field of R&D for NTDs has been evolving. In the late 1990s, the 
effectiveness of PPP is considered unproven, and the plethora of PPPs may be considered as a 
waste of public money and duplication. In the last 20 years, their main functions shift towards less 
of a funder but more towards integrating and coordinating multiple industries and academic 
partners and contractors along the drug development pipeline105. The primary source of funding 
remains the public and philanthropy106, and PDPs have become the main actor for the majority of 
neglected disease drug R&D.  
 Other approaches to stimulate R&D for NTDs have also been advocated, most commonly 
categorised as pull and push mechanisms107. The ‘pull’ in the form of research grants, subsidies or 
tax credits, are meant to stimulate upfront the research costs. Though this signals interest for a 
change, there is no evidence on their impact. It may address one factor, but as high costs alone do 
not explain the shortfall in R&D these mechanisms warrant further scrutiny. The ‘pull’ factors aim 
to address the lack of viable markets and are designed to create or secure a market (improving 
likelihoods of return of investments). These include patents or market exclusivity, purchase pre-
commitments (or advanced market commitments, exist for vaccines for example) and regulatory 
Box 2 
Miltefosine (MF): anticancer drug candidate that was discovered as anti-leishmania in the mid-1980s. WHO 
TDR together with Asta Medica (later Zentaris), supported the development through numerous clinical trials 
in India. MF was officially registered to treat VL in India in 2002.  
Paromomycin (PM): aminoglycoside that originally licensed by Farmitalia, and first used to treat VL in 
Kenya in the 1980s. WHO sponsored its development in India, which continued by International Dispensary 
Association (IDA, the Netherlands). Institute of One World Health (currently PATH) took it over for Phase III 
trial and eventually PM was registered to treat VL in India by 2006. Currently, a pharmaceutical company, 
Gland Pharma (India) manufactures and markets the drug. 
Liposomal amphotericin B (LAMB): since the discovery of the liposomes in the 1970s, trials were ongoing 
to compare LAMB versus conventional Amp B and/or other lipid formulations. These studies were pivotal 
to apply for a New Drug Application (NDA) to the United States Food and Drug Administration (US FDA) in 
1997. WHO reached an agreement with the company, NeXstar Pharmaceuticals Inc (later Gilead) to evaluate 
clinically AmBisome for the treatment of kala-azar. Although AmBisome was also initially developed for 
other purposes, the collaboration between NeXstar, Inc., and TDR has resulted in the first formal worldwide 





incentives such as the Priority Review Voucher (PRV) programme. PRV was created in 2007 as an 
incentive for manufacturers when registering a product with US FDA for tropical disease 
indication 108. Knight’s Therapeutics, the current owner of miltefosine, received the PRV in 2014 
and had sold it to Gilead for US$125 million. The overall evidence of PRV impact is so far mixed as 
impact of PRV on improved access is yet to be confirmed109,110. 
 
TACKLING NTDS IN THE ERA OF UNIVERSAL HEALTH COVERAGE 
 Universal health coverage (UHC) is defined by WHO as “ensuring that all people can use 
the promotive, preventive, curative, rehabilitative and palliative health services they need, of 
sufficient quality to be effective, while also ensuring that the use of these services does not expose 
the user to financial hardship”92. UHC4 has become a guiding principle for countries post-2015: 
the Sustainable Development Goals (SDG) era, and there has been a strong push to consider NTDs 
control and elimination efforts within this frame111.  
 Within the 17 SDG, health is pronounced under the SDG3 (“Ensure healthy lives and 
promote well-being for all at all ages”) and in specific target 3.3, neglected diseases is mentioned. 
In the broadest interpretation, NTD interventions may impact poverty (SDG1), hunger (SDG2), 
education (SDG4), work and economic growth (SDG8) and reducing inequalities (SDG10)112. The 
cross-cutting contribution of the end of NTDs to improve the prospects of attaining the SDGs is 
linked to the characteristics of NTDs ‘sufferers' – the poor, but not only in low-income countries 
but also in middle and high-income countries113. The unequal distribution of NTDs means that the 
public health impact of NTDs may not be obvious at the country or national level but especially 
hard for the lower socioeconomic groups114. This ‘social gradient’ for NTDs have been 
demonstrated for Buruli ulcer, dengue, HAT and VL. For the latest, despite a free provision of 
diagnosis and treatment, 25-75% of households affected by VL experience some type of financial 
catastrophe19,113,115.  
 Within this context, it is important to note that the two targets set by WHO/World Bank 
framework to monitor progress towards UHC116, i.e. 1) minimum 80% essential health services 
coverage and 2) 100% financial protection from out-of-pocket payment for health services, seem 
appropriate for NTD programmes. This is because NTD patients and their families often fall into 
the medical poverty trap, through what is known as Catastrophic Health Expenditure (CHE). CHE 
is defined as out-of-pocket payment exceeding 10% of annual household spending or 40% of non-
subsistence spending117,118. Access to NTD interventions reduces the financial burden on health 
systems in almost all countries119. 
 In endemic countries where intervention for NTDs is mainly reliant on case detection and 
management by the health services, NTD burden can be considered as a proxy for inequitable 
access to health systems. Universal access is therefore fundamental to achieve universal health 
                                                             
 
4 There are three dimensions in the so-called UHC cube: 1) extending coverage to individuals previously not covered; 
2) extending coverage to services that previously not covered; 3) reducing direct payments to protect from financial 
hardship (Source: WHO) 
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coverage and is often defined in three aspects: physical or geographical accessibility, financial 
affordability and acceptability (willingness of the people to utilise a service or intervention)120,121. 
For visceral leishmaniasis, access to affordable, quality-assured medicines and diagnostic is a 
prerequisite, while for other forms (cutaneous or mucocutaneous) the recognition of their 
psychosocial impact is critical to have better burden estimates.  
 There is a case to be made towards investment in leishmaniasis control, which is aligned 
as well with the ‘rights to health' approach for NTDs. People affected by leishmaniasis are the 
poorest of the poor or marginalised groups of the community122,123, and impoverishment due to 
leishmaniasis is not unheard of. Translating UHC into reality requires the inclusion of 
leishmaniasis care, and other NTDs interventions, in the UHC benefit package96.  
 Lack of NTD prioritisation is illustrated by very little domestic investment from endemic 
countries. Despite several NTDs master plan and regional strategies in some region, including 
Africa, the progress is variable, and NTDs are often absent from national health plans and budgets, 
let alone in other sectors. Reliance on external support, mainly from big donors or philanthropy 
foundations, jeopardises sustainability in the long run. 
 Nevertheless, the current consensus is that access to NTD interventions should form an 
integral part of UHC, with their positive effect on health gains and reduction in CHE124,125. Control 
and elimination of NTDs are sensitive indicators of poverty alleviation and UHC and should 
represent how developing countries care for the health of the poorest section of the population. 















MSF clinical officer prepares sodium stibogluconate (SSG) for a child admitted in the kala-azar ward, 










HYPOTHESIS, OBJECTIVES AND THESIS OUTLINE 
HYPOTHESIS 
 Poor access to care remains one of the barriers to a functioning leishmaniasis control 
programme in eastern Africa. The diversity and complexity of leishmaniasis mean VL control in 
this region depends on case detection and management. The current diagnostics and treatment 
options are limited, but the reasons behind are not fully understood. 
 Furthermore, even though VL care is made available, it might not be accessed optimally or 
fairly: much is left unknown on the part of community perspective and motivation to seek VL care. 
Low coverage of the health services, accessibility and availability of quality care including 
diagnostic and treatment options, and inefficient procurement and supply– remain all major 
challenges in the region. Aspects of financial, organisational and socio-cultural barriers that limit 
service utilisation, and also affordability, physical accessibility and acceptability need to be 
evaluated. For a potentially fatal disease like VL, the understanding of the determinants of access 
to care is critical. What is clear is that access to leishmaniasis care in this part of the world remains 
problematic and that the current body of literature shows critical evidence gaps.  
Therefore, the central hypothesis in this thesis is that access to care for leishmaniasis in 
eastern Africa is inadequate.  
 
OBJECTIVES  
The general objectives of this thesis are to improve our understanding on access to care in Africa, 
by documenting availability, affordability and accessibility of care, explore novel ways of 
enhancing such care, and provide insights into specific elements of access to formulate coherent 
policy recommendations for leishmaniasis in eastern Africa. 
The studies included in this thesis were framed around the following specific objectives 
(represented in Figure 10) 
 
a. Burden assessment: 
• To assess the availability of leishmaniasis care in a fragile context (Somalia) 
• To update epidemiology and burden of cutaneous leishmaniasis in sub-Saharan Africa 
• To synthesise the economic burden of leishmaniasis 
b. To examine access issues ‘upstream': 
• To summarise the current landscape of RnD for NTDs, especially Public-Private 
Partnership  
• Analyse failures of post-registration access of miltefosine (case study) 
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c. To examine access issues ‘downstream': 
• To analyse access barriers to the effective supply chain of leishmaniasis diagnostics and 
medicines in eastern Africa  
• To explore access barriers to care for leishmaniasis from the community perspectives in a 
high endemic area of Gadarif, Sudan 
Figure 10 Overview of the thesis by research questions 
 
THESIS OUTLINE 
The thesis result is divided into three sections structured around the specific objectives described 
above, that each look into the different part of the access continuum applied to leishmaniasis care. 
 In the first section on burden assessment, we present three studies, primarily based on 
systematic reviews and my participatory observation during my fieldwork in Somalia, Ethiopia 
and Sudan. The second section provides two studies of the more upstream aspects of access, i.e. 
an analysis of the role of Public Private Partnership as a solution for the gap in R&D for NTDs, and 
a case study of the post-marketing access to the first and so far the only oral medicine for 
leishmaniasis, miltefosine. The launch of miltefosine was considered as a breakthrough in 
leishmaniasis control, but the drug never became as widely available and affordable as 
anticipated. We looked into the reasons why. The third section contains two studies that 
investigate the access barriers in the field, from two perspectives: the health system and the 
OBJECTIVE: STUDY ACCESS UPSTREAMOBJECTIVE: BURDEN ASSESSMENT
Research Question(s) 1
1.a What is the status of VL 
care in Somalia as the fragile 
state?
1.b What is the burden of 
Cutaneous Leishmaniasis in 
Africa?
1c. What is the leishmaniasis 
economic burden? 
Research Question(s) 3:
3.a. What are the barriers to 
effective supply chain of 
leishmaniasis medicines and 
diagnostics in eastern Africa?
3.b. What are the access barriers to 
care from the community 
perspective? (Gadarif, Sudan)
Research Question(s) 2
2.a. What are the evidence that 
Public Private Partnership could 
tackle lack of RnD for neglected 
diseases?
2.b. What are the reasons for access 
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community. The first analysis, on the health system, examines the supply chain for leishmaniasis 
diagnostics and medicines in the endemic countries of eastern Africa. In the second study 
conducted in Sudan, we studied the community perspective in a hotspot of VL through a 
qualitative study (see Box 3). As the last chapter, we summarise critical findings for each of the 
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Windows in feeding centre for the displaced and refugees during the famine in Mogadishu, Somalia, 2011 
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 In 2015 when this project started within the Euroleish network, it was made clear that this 
research should be done in accordance with current agenda of leishmaniasis control and research 
in eastern Africa. To do this, we consulted with the main stakeholders namely Médecins Sans 
Frontières, and members of KalaCORE Consortium (a UK-aid funded programme to tackle 
leishmaniasis in Africa and Asia, 2014-2018). Based on the unmet needs and not to duplicate 
efforts, the studies in this thesis were planned and informed to these stakeholders. Apart from 
that, Euroleish.net as a European Union Marie-Sklodowska Curie Innovative Training Network 
Programme also encourages collaboration with non-academic partner(s), which for this project is 
represented by MSF Access Campaign, Geneva.  
 For the burden assessment, the fact that at least two countries in these regions are mired 
by active conflict (Somalia and South Sudan) made a focus on fragile settings necessary. I worked 
in these two places as physician and in Bakool region, Somalia, managed a 30-bed kala-azar ward 
for 6 months in 2009. A monograph on VL care and epidemiology in Somalia, documenting current 
situation in 2016-2017 was warranted. A systematic review was performed, added with MSF 
programme data and context analysis. 
 Another gap in knowledge was for cutaneous leishmaniasis in Africa, as most control 
efforts are directed for VL. A clear idea on the burden was proposed as possible study, to provide 
a firm baseline for further research or intervention. A systematic review was planned. Similarly, 
the economic burden of leishmaniasis was also synthesised through a systematic review.  
 Though a literature review is needed in every start of scientific endeavour, in this thesis 
the systematic review method was employed in the highest standard (learned from my Cochrane 
review experience) and strict, meticulous adherence to a pre-defined, published protocols 
(registered in the international register platform for systematic reviews called PROSPERO: 
https://www.crd.york.ac.uk/prospero/). PRISMA guidelines were followed in all ensuing 
publications.  
 This methodology was also partly deployed, combined with a landscape analysis to build 
the second part of access upstream. Here, a joint systematic review was performed to assess if 
public-private partnership (PPP) was a solution to tackle neglected tropical diseases. A synthesis 
of this research question applied to R&D for leishmaniasis is presented, followed by an in-depth 
case study on miltefosine, the only oral drug for VL. The insights included in this part were 
complemented with my participant observations during the regular meeting of two main core 
groups that I was invited to be part of the MSF NTD Working Group who meets every quarter, and 
also of the WHO Working Group on Access to Leishmaniasis Medicines which was established in 
2016 and had met four times to date. Interacting with the key players on leishmaniasis control in 
my region of interest were useful in understanding issues that are not found in published 
literature but as well to shape my project in a way that can be impactful, with steadfast focus on 
public health. 
 These have contributed to the design of the third part on access downstream: studies on 
access barriers at two different levels. What were the barriers at the health service level, their 
supply chain? What remains the barriers at community level? As these research questions 
fundamentally ask what and why (the reasons behind), qualitative research methodologies 
were chosen as the best to answer them. Admittedly, the lack of quantifiable data on these two 
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aspects have led also to this choice. Qualitative methods were definitely an eye-opener for me in 
delving deeper beyond numbers: choosing the right theoretical framework, collecting data 
through Focus Group Discussions and In-depth Interviews, and eventually analysing the immense 
text data generated from this method.  
 For the supply study, in depth interviews were conducted with main stakeholders at global 
and national level from Ethiopia, Kenya, Somalia, South Sudan, Sudan and Uganda. The community 
study was conducted in a hyperendemic hotspot in Sudan, in a collaboration with the Kala-azar 
Research Center (KRC), based in the University of Gadarif and facilitated by KalaCORE 
Consortium. Gadarif state in eastern Sudan bears 80% of the VL cases in Sudan, with 12 health 
facilities providing care (3 with external support, one MSF and 2 DNDi). The field sites are the 3 
main localities in this state, where I spent in total of 6 weeks.  
 This thesis is presented as collection of 6 articles that are already published in 





Kala-Azar Research Centre (KRC) is part of the Faculty of Medicine, University of Gadarif or al-Qadarif in the eastern 
part of Sudan. The centre has been created to facilitate research from this endemic area. KRC became a member of 
Euroleish network since 2017 and helped to implement and facilitate the access barrier study in Sudan.  
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After the initial visit in July 2016, the field work started in 2017. A training on qualitative research methods was 
organised for the local teams, prior to piloting the techniques in real life setting.  
 
The people of Gadarif relies on agriculture for their livelihood, with sesame and sorghum as the main crops. The state 
is considered as one of the pillars for food security in Sudan. Smallholder farmers of the area came from various areas 
of Sudan and beyond since.  
 
Traditional healers can always be found in the market selling remedies to all kinds of ailments. 
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Interview and focus group discussions (FGD) were conducted in gender and age specific groups. Facilitators were 
previously trained using piloted topic guides, and daily debriefing was done to analyse and adjust the topic guides.  
 
Prior to visiting the villages, the team called a community meeting. The village leader(s) were informed, and supported 
the research team in the study. Former kala-azar patients, caretakers and health care workers made up the groups.  
 
The means of transport in Gadarif are limited. The most common means to move around are these trucks, rickshaws, 
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A child at the kala-azar ward with burnt marks on his belly as a result of traditional healing to the 
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A kala-azar patient receiving liposomal amphotericin B. Injectables made up most of the medicines used 
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 Role of Public-Private Partnership in R&D for leishmaniasis** 
 
 This chapter provides a brief summary on the state of knowledge of neglected diseases 
research and development which as a context for leishmaniasis. I synthesised the shortcomings 
of the current research and development (R&D) system for neglected tropical diseases (NTDs) 
that result in the lack of effective diagnostics and medicines, followed by an overview of existing 
remedies specifically on the role Public-Private Partnership (PPP) as an alternative approach.  
Current R&D for NTD: diagnosis of problems 
 The current system for R&D of new medicines does not adequately meet the needs of the 
majority of the world's population1. Research priorities do not reflect the public health interest 
and has been termed as 10/90 gap, i.e. an imbalance between what is spent on medical research 
for health needs of people in developing countries (10% of global funding) and the percentage of 
preventable deaths occurring in those countries (90%)2. The R&D process has traditionally been 
rewarded through profit expected from a market exclusivity either through patent or other 
‘monopoly’ (data)3. For diseases such as NTDs that primarily affect populations with little 
purchasing power, there is virtually no (lucrative) market and therefore, insufficient incentive for 
industry to invest in R&D for them. This is evident when two systematic assessments show that 
between 1975-1999 only 1% new therapeutic products had been developed for neglected 
diseases4. Between 2000-2011, among the 336 new chemical entities, only four compounds (1%) 
had neglected diseases as indication (and these were malaria and tuberculosis)5. Latest data 
revealed that between January 2012, and September 2018, 256 therapeutic products reached the 
market, but only eight (3 %) targeted neglected diseases6. During this period, only two new 
chemical entities (1%) were approved for neglected diseases: bedaquiline for tuberculosis in 
2012 and tafenoquine for malaria in 2018. Approved products for NTDs were typically 
repurposed compounds, new formulations, or drug combinations. 
                                                             
 
** The information contained here is loosely informed by a paper ‘Are public-private partnerships the solution to tackle 
neglected tropical diseases? A systematic review of the literature’. Aerts, C, Sunyoto, T. et al Health Policy , Vol. 121, No. 
7, 2017, pp. 745-754 
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 In 2016, G-Finder estimated that the total global funding for neglected diseases reached 
US$ 3,2 billion, but 70% were still allocated for HIV, tuberculosis and malaria7. The R&D process 
can be described in short as follows. Governments fund the early-stage basic research through 
mostly public laboratories or academic institutions. The pharmaceutical industry then takes up 
promising leads and invests further in the development of a product, carrying out clinical trials 
to test if a medicine is safe and efficacious, then filing for regulatory approval. If successful, firms 
then market, sell, and distribute the medicine, usually under the protection provided by one or 
more patents and other regulatory measures; the higher prices enabled by these patents allow 
firms to recoup their R&D investments and are paid by consumers or by public or private health 
insurance.  
 Initially, intellectual property or patent protection was designed to motivate investment 
to pharmaceutical R&D. By incentivizing innovation, as exchange the invention is disclosed and 
the public is meant to benefit from the innovation. Patents prohibit the manufacture, use or sale 
of an invention without the patent-holder’s permission, for a minimum 20-year period. However, 
it has been shown to be inefficient over the years as number of new drugs approved by the US 
Food and Drug Administration (FDA) per US$ billion spent on R&D halved every nine year8. With 
only few true breakthrough innovations, practices such as ‘evergreening’ to extend patent 
duration and increase of ‘me-too’ drugs (those that merit another patent despite little or no 
significant therapeutic benefit compared to existing drugs) are common. Diseases that do not 
offer such profit are simply sidelined, for example vaccines or medicines for Ebola – the viral 
Figure 1. Proportion of products focused on neglected disease between 2000-2011. Source: Pedrique et 
al, 2013. Lancet Global Heath https://doi.org/10.1016/S2214-109X(13)70078-0 
 
 
117 Chapter 4 
RESULTS 
haemorrhagic fever which caused a massive outbreak in 2014-2016 in West Africa- though the 
candidate has been sitting on the shelves since 20059. Lifestyle medicines provide more longer 
term sales profit than short-course antibiotics, thus pipeline for new antibiotics is empty despite 
an impending global health crisis of antimicrobial resistance10.  
 Focusing on short-term profit also encourages less data sharing and a rise in the business 
practice of the major pharma to target biotech companies (often the smaller, productive ones) for 
acquisition or partnering to avoid riskier stages in the R&D cycle11. Big pharmaceutical 
corporations spend almost twice as much on sales and marketing than R&D. Practices to inflate 
share prices, such as share buybacks - when a company buys back its own shares from the 
marketplace in order to boost the value of the remaining stock still held by shareholders – are 
prevalent.  
 In recent years, drug prices have been increasing and create a significant barrier for 
patients and health systems12. One example is the new antiviral to treat hepatitis C, sofosbuvir, 
which was priced at $84,000 per treatment course, or $1000 per pill — despite the actual cost of 
production of $62. Gilead, the drug’s manufacturer has earned $40 billion in profit in three 
years13. In addition, sofosbuvir was the product of over 10 years of research funded by the public 
sector (US Department of Veterans Affairs and NIH-funded research at Emory University as well 
as NIH small business innovation grants), which then developed by Pharmasset and later 
acquired by Gilead Science14,15. Old, off-patent drugs have become also source of revenue. One 
archetypal example is pyrimethamine (Daraprim®) for toxoplasmosis whose price was hiked by 
5500% from to $750 per pill16. Other examples abound, ranging from off-patent drugs to treat 
diseases such as heart failure, epilepsy and multi-drug-resistant tuberculosis to newer cancer 
medicines 3. The high prices of medicines have led to treatment rationing and public outcry. The 
high price tag is charged according to what the market can bear , even when the company has not 
invested in the drug’s development process17–19. 
 The pharmaceutical industry justifies the high drug price based on recouping their R&D 
investment. The cost to develop new drug from the industry-supported research by the Tufts 
Center for Drug Development estimated the cost of bringing a successful therapy to market at 
US$2.6 billion20 (up from US$1 billion a decade earlier21) which consists of $1.2 billion out-of-
pocket from company and $1.4 billion time costs (expected returns that investors forgo when the 
drug is in development). Product development partnership such as Drugs for Neglected Disease 
initiative (DNDi) estimated the cost to develop a New Chemical Entity (NCE) at US$39-52 million, 
but up to $130-195 million when risk of failure is taken into account22.  
 However, for NTDs including leishmaniasis, the cost for R&D has been argued to be a less 
credible barrier than the lack of viable market23. The ‘market failure’ has been compounded with 
the ‘public policy failure’ that allow the situation to persist. This means that the pharmaceutical 
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industry does not operate in free market but a highly manipulated one with various regulatory 
loopholes that can be exploited24. Furthermore, neglected diseases often require solutions that 
go beyond single drugs, such as interventions and approaches which include combinations of 
drugs (treatment regimens) diagnostic tools, and knowledge of how best to administer drugs for 
different patients (e.g. children).  
 In summary, the main shortcomings of the current R&D for NTDs lie in the bigger picture 
of the insufficiencies of the pharmaceutical R&D system. First, patients’ needs and public health 
impact are not necessarily prioritised. Second, innovation is not linked to equitable access even 
more when there is no commercial incentive to drive it. Market incentives aligned with 
intellectual property/exclusivity do not adequately address health needs in low and middle 
income countries. The out-of-reach high price of medicines and the financialization of the 
pharmaceutical R&D are symptomatic of deep-entrenched problems. It has increasingly become 
evident that development of new tools for NTDs cannot be incentivised through the usual patent 
system and corrective actions from the public are needed. Governments are ultimately 
responsible for ensuring that people’s health needs are met. 
 
Bridging the gap between public health needs and private commercial interests – is it 
possible?  
 Initially, to fix the “broken system”, several schemes or proposals were suggested in order 
to attract private sector R&D capacity back into needed areas, what are called “push” and “pull” 
mechanisms. The drug discovery and development process is risky and difficult, with bottlenecks 
looming at various steps (see Figure 2).  
  
Figure 2. Gaps in the drug development process for NTDs can arise. Source: Fatal Imbalance, The Crisis 
in Research and Development for Drugs for Neglected Diseases, MSF/DNDi report, 2001 
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 “Push” mechanisms are meant to reduce upfront costs inherent to R&D activities, and can 
include tax credits, R&D grants, and support for clinical trials. “Pull” measures help create a 
market for drugs or increase their profitability through a variety of rewards that are contingent 
on successful drug discoveries. Examples include the creation of purchase funds, advanced 
market commitment (AMC) or forms of “patent exchange,” whereby a company would invest in 
developing a drug for a neglected disease and gain advantage for other drug, either through 
accelerated approval or time to market, such as the Priority Review Voucher (PRV) programme 
(see Table 1 for overview of some of these pull and push schemes).  
Table 1 Push and pull mechanisms  for research and development of neglected diseasesa 
Push mechanisms Advantage(s) Disadvantage(s) 
R&D grants  Encourage small companies to step in Moral hazard; asymmetry of 
information or adverse selection 
(exaggerate R&D to get more funding) 
R&D tax credit Widely used to stimulate research in 
specific area 
More benefit for large companies with 
large tax burden 
Patent pools Avoid negotiation with each patent 
holder, better collaboration and 
transparency  
Have been poorly used. Critic says risk 
of anti-competitive behaviour due to 
cartel information 
Pull mechanisms Advantage(s) Disadvantage(s) 
Advanced market 
commitment (AMC)* 
Reward is only granted once the 
product is developed 
Time-inconsistency problem; difficulty 
in setting the right AMC price; may not 
appeal to small companies 
Transferable IP 
right** 
Potentially attractive for big company  
Priority Review 
Voucher (PRV) $ 
Earlier market access in high-income 
countries for the awardees 
May not reward true innovators (drugs 
may have been used for long outside 
USA) 
No obligatory access strategy 
a The list is not exhaustive. Adapted from Aerts et al (2017); IP- Intellectual Property, * AMC: donors make a prospective commitment 
to purchase a successful product at a pre-specified price for a fix quantity; ** Transferable IP Rights: companies are awarded an IP 
extension for a product of their choice conditional on successfully bringing an NTD product on the market; $ PRV is granted by USFDA 
upon successful registration of NTD product which can be used by the awardee (or can be sold to third party) for faster review (6 
months instead of 10) of a potential blockbuster drug candidate 
 
 The combination of the two or mixed schemes tend to be preferred over push and pull 
schemes, but the equilibrium between push and pull incentives is still to be defined in the context 
of NTDs. One example comes from for rare diseases, through regulation such as the Orphan Drug 
Act in the United States (since 1983) and in Europe (since 2000)25. Though there are different 
details between US, Europe, Japan and other countries with similar law, the orphan designation 
was basically put in place to stimulate R&D for with insufficient expected return on investment 
to justify the investment. These ‘rare diseases’ definition also varied, e.g. diseases affecting 
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<200,000 cases in US, and in EU with prevalence below 5/10,000 population. The incentives 
ranged from market exclusivity (7-10 years), reduced/waived fee, regulatory or technical 
assistance, and tax credits or subsidies for clinical trial. Recently there has been increasing call to 
review these regulation as precision medicine is on the rise and concern that these orphan 
designation does not benefit the patient26–28. Societal agreement is clearly needed29.  
 Although the PRV appears to be a good idea at first sight, there has been little evidence in 
the last decade that their benefits are going to where they were intended. PRV started in 2007 for 
tropical diseases30, then extended to rare paediatric diseases in 2012 and medical 
countermeasures in 2016 (the latest for example, new drug with smallpox indication, given to 
SIGA and has been sold for US$ 80 million to Ely Lilly). As of February 2019, 22 PRVs have been 
awarded (eight for tropical diseases -for malaria, tuberculosis, leishmaniosis, cholera, river 
blindness, and Chagas-, 14 for rare paediatric diseases, and one for a medical counter-measure). 
(see Table 2).  
Table 2 Priority review voucher recipients for neglected tropical diseases since 2007 
Drug Year Company Disease Use of the voucher 
Artemether-
lumefantrine 
2009 Novartis Malaria Unsuccessfully used by Novartis to 
accelerate the review of Ilaris 
(canakinumab). 
Bedaquiline 2012 Janssen Multi-drug resistant 
tuberculosis 
* 
Miltefosine 2014 Knight 
Therapeutics 
Leishmaniasis Sold to Gilead Sciences for $125 million. 
Gilead announced it had used the 
voucher in support of its NDA filing for 
its HIV drug Odefsey. FDA approved the 
drug in six months on 1 March 2016.  
Vaxchora 2016 PaxVax Cholera (prevention) Unused. Likely sold to Gilead for ~$200 
million 
Benznidazole 2017 Chemo Group Chagas disease ** 







2018 GSK and MMV Malaria ** 
Triclabendazole 
(Egaten®) 
2019 Novartis Fascioliasis (liver flukes)  
 
 The first three PRVs for tropical disease were awarded to an antimalarial drug 
(Coartem®), a multidrug resistant tuberculosis medicine (bedaquiline) and the first oral 
treatment for leishmaniasis (miltefosine). Among these 3 drugs, two were already developed and 
registered outside the US well before the voucher system was launched 31,32. The voucher has 
been valued speculatively based on the competitive benefits from earlier entry relative to 
competitors. To date, the sale prices range from $67.5-$350 million, and the most recently 
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disclosed sale price was $110 million. At least two companies have used the voucher for their 
own drugs, and the sale prices of eight PRVs have been publicly disclosed. Critics of the scheme 
have mainly pointed out that companies may win the voucher despite not being involved in the 
drug development (such as the case for miltefosine)33. Furthermore, the recipients are also not 
obliged to ensure access. Amendments to fix these loopholes have yet to The true impact of PRV 
in stimulating R&D for NTDs have yet to be determined 34,35.  
The rise of Public-Private Partnership (PPP) in the field of R&D 
 Partnerships, coordination and better governance have been emphasised as a necessity 
for NTDs36. International control initiatives have naturally brought different stakeholders 
together, but responding to the lack of treatment for diseases associated for poverty was 
recognised as one of the motives behind emergence of PPPs since late 1990s37. PPPs†† are indeed 
diverse in nature and exist in various fields (other than health). In the field of R&D for NTDs, it 
has gained prominence as an example of the ideal way when the drug development expertise of 
the pharma industry combined with neglected disease expertise of the public sector38. They are 
considered to have positive impact on health outcomes, innovation, development speed and cost-
efficiency39,40. Some of these PPPs have been evaluated and they all invest a lot in promotion and 
public relations. There is however little conceptualisation and in-depth empirical investigation 
into how PPPs actually work41.  
 The roles of partnerships in NTDs are – but not limited to – product development 
partnerships (PDPs) and partnerships based on products delivery and uptake (PPPs Access). 
Respective examples of such partnerships include the Onchocerciasis Control Program, Medicine 
for Malaria Venture, Drug for Neglected Diseases initiative (DNDi) and many others. Other types 
of PPPs include financing and coordinating partnerships. The different types of partnerships are 
not mutually exclusive: while it is more common for partnerships to dedicate themselves to one 
particular activity, some use a hybrid model.  
 Some of the key dimensions of PPPs include: shared objectives, joint investments, 
bundling, sharing of risks, sharing of benefits, inter-organisation relationships, contractual 
governance, power and information sharing. The typical strength of a PPP that is often mentioned 
lies in the distinct roles of the private and public parties involved. Private companies bring in 
certain technical knowledge and skills and they are generally considered good at innovation, with 
a certain dose of entrepreneurship and managerial efficiency. Public parties are considered 
                                                             
 
†† One of the many definitions of a PPP is the following: ‘An arrangement – formal or informal – between two or more entities, of 
which one public and one private party, that enables them to work cooperatively towards shared or compatible objectives, and in 
which there is some degree of shared authority and responsibility, joint investment of resources, shared risk taking and mutual 
benefit’. 
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necessary for creating the right enabling environment, promoting social justice and ensuring 
public accountability. Some success factors include: (1) clarity of roles and responsibilities and 
some ground rules for working together (2) a common understanding of mutual benefits (3) a 
clear vision of objectives (4) sound communication, shared planning and decision making and (5) 
leadership. These should not be taken for granted as corporate cultures in the private sector, are 
often quite different from those in (semi-) government institutions. This means that smooth 
cooperation is not automatic.  
 The evidence that PPPs are actually instrumental in achieving better health or 
development in general has varied so far11,37. PPPs in health are diverse, which makes it 
challenging to evaluate their performance. There is a large diversity in the extent to which they 
are successful – or claimed to be successful – even though the empirical evidence is scanty41,42. 
Some of the critical success factors for PPPs have been reported on and appear to be universal. 
There is much less consensus about the precise criteria to be used, but several sets of criteria 
already have been created. More research on what tools and ways to evaluate a particular PPP is 
desirable. For PDP, defining research priorities and the target product profiles (TPPs) – as has 
been done by WHO in the case of medicines, vaccines and diagnostics for malaria – can promote 
targeted use of resources to respond to public health needs43.  
 
Table 3 PPP for leishmaniasis* 
Partnership(s) or Organisation leading the 
partnership 
Tools 
The Special Program for Research and Training in 
Tropical Disease (TDR) 
PDP: Drug development (Miltefosine and 
Paromomycin)  
 
WIPO Re:Search Consortium (World Intellectual 
Property Organisation) 
Facilitate coordination for product development 
 
DNDi (Drugs for Neglected Disease Initiative) PDP: Drug development 
Access 
The Infectious Disease Research Institute PDP: Vaccine development 
 
*Adapted from Aerts et al, 2017 
  
Transformation of the innovation system 
 International debate and proposals for reform have ensued, including the 
recommendation that governments begin negotiations over a binding medical R&D convention 
to address systematic, long-standing problems with innovation and globally equitable access to 
medicines. Despite the emergence of many new approaches to generating R&D that meets the 
needs of poorer populations, efforts remain ad hoc, fragmented, and insufficient. An R&D treaty 
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or agreement has been proposed in effort to address four areas where the system remains 
particularly weak: affordability, sustainable financing, efficiency in innovation, and equitable 
health-centred governance. Transforming the current system definitely requires effective tools 
to enforce medical R&D as a global public good, based on the understanding that a politically and 
financially sustainable system will require both fair contributions from all, and fair benefit-
sharing for all. 
 The World Trade Organization Agreement on Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) is the most relevant international legal framework that sets minimum 
requirements for the protection of intellectual property for WTO Members. Its use must be 
encouraged and actually served as opportunity for governments more frequently than previously 
thought44. Another novel tool developed by WHO/TDR is the Portfolio-To-Impact (P2I) Model 
with the aim to estimate minimum funding needs to accelerate health product development from 
late stage preclinical study to phase III clinical trials, and to model the impact of such product45.  
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Access to health care remains problematic for people living in remote areas or places affected by conflict. 
The Baidoa region in southern Somalia is endemic for kala-azar, amongst other health problems.  
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SUPPLEMENTAL FILE 1: IN-DEPTH INTERVIEW GUIDE 
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SUPPLEMENTAL FILE 2: TOPIC GUIDE AND GUIDELINES FOR FOCUS GROUP DISCUSSION (IN ENGLISH 
AND ARABIC) 
TOPIC GUIDE AND GUIDELINES FOR FOCUS GROUP DISCUSSION 
INTRODUCTION: these guidelines are to be used for conducting Focus Group Discussions (FGD) within a study 
to understand community perspective on access to care for this disease in Gadarif and the challenges associated 
with it. Information sheet and informed consent would first be solicited from participant before organizing and 
starting the FGD.  
Participants: Community members from selected villages in the localities of el Rahad, East Galabat or Al Qureiha 
(representing the catchment area of Um el Kher, Basunda and Tabarakallah hospitals, respectively).  
Participant Consent: Participants will sign a consent form to participate in the FGD. One copy of the informed 
consent form should be given to participants and a second copy should be kept by the focus group facilitator. 
Participants would be informed if any audio-taping will be used for data collection.  
Demographic data: It is important to collect anonymous demographic data from focus group participants. We 
will use an enrolment form with few key demographic details from the participant (age, sex, occupation, 
duration of living in the village).  
Facilitator/Moderator: only trained person will take this role.  
Discussion guides: Note that this topic discussion guide is meant to facilitate structuring the FGD by highlighting 
the topics that need to be covered. It is not to be used rigidly (like a questionnaire), yet the facilitator encourages 
participants to explore topics in depth, to reflect, to raise their own issues, etc. 
Time and Place: The FGD can last between 45-90 minutes and can have breaks in between for refreshments. 
Participants need to receive clear details of where and when the focus group will take place and how long it will 
last.  
DISCUSSION GUIDE 
Facilitator’s welcome, introduction and instructions to participants  
Welcome and thank you for volunteering to take part in this focus group. You have been asked to participate as 
your point of view is important. I realise you are busy and I appreciate your time. 
This discussion is designed to assess your current thoughts and feelings, or experience, about visceral 
leishmaniasis, a disease that is commonly found in this state. The FGD will take no more than two hours. May I 
tape the discussion to facilitate its recollection ? (if yes, switch on the recorder) 
Anonymity: Despite being taped, I would like to assure you that the discussion will be anonymous. The tapes will 
be kept safely in a locked facility until they are transcribed word for word, then they will be destroyed. The 
transcribed notes of the focus group will contain no information that would allow individual subjects to be linked 
to specific statements. You should try to answer and comment as accurately and truthfully as possible. I and the 
other focus group participants would appreciate it if you would refrain from discussing the comments of other 
group members outside the focus group. If there are any questions or discussions that you do not wish to answer 
or participate in, you do not have to do so; however please try to answer and be as involved as possible. 
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Ground rules 
• The most important rule is that only one person speaks at a time. There may be a temptation to jump 
in when someone is talking but please wait until they have finished. 
• There are no right or wrong answers 
• You do not have to speak in any particular order 
• When you do have something to say, please do so. There are many of you in the group and it is 
important that I obtain the views of each of you 
• You do not have to agree with the views of other people in the group 
• Does anyone have any questions? (answers).  
• OK, let’s begin 
Warm up 
• First, I’d like everyone to introduce themselves. Can you tell us your name ? 
Introductory question: I am just going to give you a couple of minutes to think about what you know about 
leishmaniasis or kala-azar, or if you know someone who has kala-azar in the past. Is anyone happy to share his 
or her experience? 
Guiding questions 
1. What is kala-azar and what do you think about it? (causes, transmission, symptoms, prevention…) 
2. When someone is thought to have kala-azar, what does it mean? (perception of severity of disease, 
meaning...) 
3. What are the attitudes of you or other people towards the disease? (What did people think/say/do?) 
4. If people seek care for VL, to where and why? (Beliefs and thought, preferences for healing/healthcare 
services, including perceptions of services rendered by different providers: traditional healers, hospital...) 
5. What made people go to health centre or hospital? (explore positive or negative perception towards 
available health care…-though this may imply general health seeking behaviour towards any illness, the 
focus will remain for VL) 
6. What are the main issues around about kala-azar here? 
7. What made it difficult to get care on time for VL? (explore accessibility: geographic accounting for seasonal 
difference, cultural/gender/age, administrative and financial barriers…) 
8. Has anyone ever had experience/know of an experience when getting care for VL and want to share that? 
(either positive or negative, including diagnosis, treatment… ) 
9. What do you think about the current available care for VL? Or Do you think the current available care for VL 
is good? If not, why not? (similar questions for outcomes, efficiency, teamwork and communication) 
10. What are your thoughts to overcome the challenges regarding this disease? Or are there ways that could 
have been done to make it easier/better for you? (explore different options i.e. linked to shared barriers 
before, either for specific aspect or more general…)  
Concluding question 
• Of all the things we’ve discussed today, what would you say are the most important issues you would 
like to express about access barrier to this disease? 
Conclusion 
• Thank you for participating. This has been a very successful discussion 
• Your opinions will be a valuable asset to the study 
• We hope you have found the discussion interesting 
• If there is anything you are unhappy with or wish to complain about, please contact the local PI or speak 
to me later 
• I would like to remind you that any comments featuring in this report will be anonymous 
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 التحكم بسياق المواضيع وإرشادات للنقاشات الجماعية
 
وجهة نظر المجتمع في التحصل قاشات الجماعية في دراسة لفهم هذه االرشادات صممت إلجراء الن مقدمة:
على الرعاية الصحية من هذا المرض في القضارف، والتحديات المصاحبة له. بداية يتم التحصل على دفتر 
 المعلومات و استمارة الموافقة من المشارك ومن ثم يتم إجراء النقاشات الجماعية.
د والقالبات الشرقية )يمثلون التجمع في منطقتي اختيارهم من محلية الره: أفراد من المجتمع تم مشاركينال
 أم الخير ومستشفى باسنده، على الترتيب(
: يقوم المشاركين بتوقيع استمارة موافقة عند المشاركة في النقاشات الجماعية، يجب اعطاء موافقة المشارك
الجماعية. في ها الشخص القائم على النقاشات للمشارك، النسخة أخرى يحتفظ ب نسخة من استمارة الموافقة
 حال تسجيل النقاشات صوتياً، سيتم إشعار المشاركين مسبقاً.
: من المهم التحصل على معلومات عن الهيكلة السكانية من المشاركين في معلومات الهيكلة السكانية
لومات عن الهيكل السكاني رة تسجيل محتويةً على بعض المعالنقاشات الجماعية، سنقوم باستخدام استما
 ا المشارك )العمر، الجنس، الوظيفة، فترة التواجد في القرية(يملؤه
 : يكون المشرف شخص مدرب ومؤهل.المنسق/ المشرف
: الحظ ان استخدام هذه االرشادات هو لتسهيل عملية إدارة النقاش عن طريق تحديد إرشادات النقاش
(، مع ذلك يجب على المشرف أن تخدامها حرفياً )مثل االستبيانع التي يجب تغطيتها. ال يجب اسالمواضي
 يشجع المشاركين على االسترسال وتغطية المواضيع بعمق لعكس أو توضيح مشاكلهم الفردية.
راحة  دقيقة و يمكن الحصول على فترات 90إلى  45: فترة النقاشات الجماعية تتراوح بين المكان والزمان
لومات واضحة عن مكان وزمان قيام النقاشات ى المشاركين ان يتحصلوا على معلتناول المرطبات، يجب عل
 الجماعية والفترة الزمنية التي ستستغرقها.
 : يقوم المشرف بالترحيب، التعريف، و توضيح االرشادات للمشاركين.إدارة النقاش
اختياركم للمشاركة نسبة في هذه النقاشات الجماعية، تم مرحباً بكم و نشكركم على تطوعكم في المشاركة 
 وجهة نظركم، أنا أعلم أنكم مشغولون وأشكركم و أقّر لكم الزمن الذي ستقضونه معنا. ألهمية
تم تكوين هذه الجلسة لنقاش لتقييم أفكاركم، أحاسيسكم وخبراتكم عن مرض اللشمانيا المعوية، المرض الذي 
ن لي بتسجيل تغرق أكثر من ساعتين، هل تسمحو، هذه النقاشات الجماعية لن تسأصبح شائعاً في المنطقة
 النقاش لتسهيل عملية جمع المعلومات الحقاً؟ )إذا كانت اإلجابة بنعم، قم بتشغيل جهاز التسجيل(.
: على الرغم من النقاش ُمسّجل، أود أن أوضح لكم أن النقاش سيحصل على سرية تامة، سيتم التحفظ السرية
كلمة، وثم سيتم التخلص منها، الحوار ق إلى حين تدوين الحوار كلمة بعلى أشرطة التسجيل في مكان مغل
المستخلص من أشرطة التسجيل سيكون مبهما بحيث ال يمكن ربط أي شخص بأي عبارة في النص، نرجو 
ن يتمنون عدم أن تكون إجاباتكم و ملحوظاتكم على أعلى مستوى ممكن من الدقة والصدق. كل المشاركي
ن خارج مجموعات النقاش. في حال وجود سؤال ال خل النقاشات الجماعية ألشخاص مالبوح بما قيل دا
 تريد اإلجابة عنه لك مطلق الحرية في عدم الرد، لكن نود منكم اإلجابة لطفاً.
 :القواعد األساسية
نتظر أحيانا النقاش للرد اللحظي، لكن رجاًء ا* أهم قاعدة هي أن ال يتكلم أكثر من شخص سوياً، قد يجذبك 
 حتى ينتهي المتحدث من حديثه.
 * ال توجد إجابات صائبة أو إجابات خاطئة.
 * ال يوجد ترتيب معين للتحدث.
* عندما يكون لديك شيء تريد قوله الرجاء عدم التردد في قوله، يوجد العديد من األشخاص في النقاش 
 معرفة وجهة نظر كٍل منكم.الجماعي، وأريد 
 قة على آراء اآلخرين.* ال يتوجب عليك المواف
 * هل يريد أي أحد منكم طرح أي سؤال؟ )أجب عليها(.
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 * أوالً أريد أي شخص منكم أن يعرف عن نفسه. الرجاء إخبارنا اسمك.
 :سؤال البداية
، بداية سأعطيكم دقيقتين لتفكروا في مرض الكالزار، أو معرفتكم بشخص أصيب بمرض الكالزار مسبقاً 
 هل يوجد أحد مستعد لمشاركة تجربته.
 :اسئلة توجيهية
 * ما هو الكالزار، وما رأيك فيه؟ )األسباب، االنتقال، األعراض، الوقاية منه ... (.
 ر، ماذا يعني ذلك؟ ) مدى خطورة المرض، المعنى(* عندما تعتقد أن أحد ما مصاب بالكالزا
 اذا يفكر الناس، ماذا يفعلون و ماذا يقولون(* ما هو سلوكك أو سلوك غيرك تجاه المرض؟ )بم
* إذا أراد الناس التحصل على الرعاية من مرض الكالزار، إلى أين يذهبون، ولماذا؟ ) المعتقدات واآلراء، 
لمنشآت، متضمناً فهم الخدمات التي يقدمها مزود صحي آخر، عالج بلدي، تفضيالت الخدمات العالجية و ا
 مستشفى ... (.
س إلى المركز الصحي أو المستشفى؟ )استرسل معه في فهم النواحي اإليجابية والسلبية ذهب النا* لماذا 
 ار(.في الخدمات الصحية الموجودة، قد تكون اإلجابة عامة ألي مرض، خصص النقاش حول مرض الكالز
 * ما هي المشاكل األساسية بالنسبة لمرض الكالزار هنا؟
ب؟) ناقشه في طرق الوصول، عالج الكالزار في الزمن المناس * ما هي الصعوبات في التحصل على
 الحالة الجغرافية مع اعتبار التغيرات الموسمية، الثقافة/ العمر/ الجنس، معوقات إدارية أو مالية(.
ديه تجربة في البحث عن الرعاية من مرض الكالزار أو يعرف تجربة شخص ما؟ * هل يوجد أحد منكم ل
 أو إيجابية، متضمناً التشخيص/ العالج ... (.) سواًء كانت سلبية 
* ما رأيك في المستوى الحالي للرعاية من مرض الكالزار؟ أو هل تظن أن المستوى الحالي للرعاية من 
جيداً لماذا؟ )اطرح نفس األسئلة عن النتائج، الكفاءة، العمل الجماعي الكالزار يعتبر جيداً؟ وإذا لم يكن 
 والتواصل(.
التحديات بالنسبة لمرض الكالزار؟ أو هل هناك طرق أخرى لو اتُّبعت ألدت  كارك لتخطي* ما هي أف
لتحديد أو لنتائج أفضلو أسهل؟ ) ناقش الخيارات المتعددة، أي أنها مرتبطة بالمعوقات السابق ذكرها، إما با
 عموما(.
 :سؤال ختامي
كل التي تعتبر من المعوقات للتحصل على * بعد النقاش الذي قمنا به اليوم، في رأيك، ما هي أهم المشا
 ض الكالزار؟الرعاية الصحية من مر
 :ختاما  
 * شكرا جزيالً على مشاركتكم، وقد كان نقاشاً مثمراً.
 الدراسة.* تعتبر آراؤكم ذات أهمية عالية في 
 * نأمل أن تكونوا قد وجدتم النقاش مفيداً.
دث منه، الرجاء التواصل مع الباحث المحلي أو التح* إذا كان هناك أي أمر يزعجك أو تريد أن تشكي 
 معي الحقاً.
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SUPPLEMENTARY INFORMATION 1A 
Information sheet 
Access to visceral leishmaniasis (VL) drugs in Africa – barriers and facilitators 
 
Background:  
The Institute of Tropical Medicine, Antwerp (ITM) is conducting a study, partnering with MSF and 
others, to investigate access barriers to quality drugs to treat visceral leishmaniasis (VL) in 
eastern Africa region. This study aims to analyse the different factors affecting access to these life-
saving medicines, from global and/or regional perspective, in order to enhance access to these 
drugs. Information will be collected for the following products: 
1. Sodium stibogluconate (SSG) - generic 
2. Paromomycin 
3. Liposomal amphotericin B (AmBisome®) 
4. Additional: meglumine antimoniate (Glucantime®), Pentostam® (SSG from GSK) 
5. Additional: rK39 RDT 
 
Interview description: 
All partners or stakeholders involved in the access to VL drugs in countries in east Africa, 
including those providing support (financial or otherwise) to the procurement and distribution 
of VL medicines (and diagnostics). We have selected your organisation and approached you to 
assist in this assessment by providing information (and your expert opinion) on any of the above 
products.  
With your consent, the interview will be recorded, and we will use a semi-structured 
questionnaire in which some information will be noted down. It should take 60 minutes of your 
time.  
Confidentiality and information security 
Participation in this study is completely voluntary and you may withdraw at any time without 
prejudice of negative consequences. All information will be kept secured and confidential. The 
study team will have access to the information arising from this interview. Information which 
could potentially identify participants will not be published without the participants’ consent, nor 
disclosed outside of the study team.  





Institute of Tropical Medicine | 155 Nationalestraat, 2000 Antwerpen | Belgium 
Ph +32 487 72 60 48 | Email: tsunyoto@itg.be | Skype: temmy.sunyoto 
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Semi-structured questionnaire for interviews for global stakeholders: Mapping 
access barriers to quality VL drugs in Africa 
Name of partner/organisation: ____________________________ 




Name of interviewer: ____________________________ 
Question guides 
1. Can you explain what is the role of your organisation related to VL in Africa? 
 Financial support 
 Procurement  




2. Which among the VL medicines (and diagnostics) that your organisation support? 





to end support 




SSG      
PM      
LAMB      
Others      
      
      
 
3. What do you think are the access challenges for VL drugs in Africa? (prompt: selection of 
products, quality, procurement, distribution, capacity…) 
__________________________________________________________________________________________________________ 
 
Follow up questions/to elaborate more on what is mentioned): 
3 a. Why is it so difficult? (e.g. forecasting the demand, …………as per the answer) 
__________________________________________________________________________________________________________ 
 
4. What do you think are barriers to access at global level? What are the reasons for that? 
_______________________________________________________________________________ 
 
5. What do you think are barriers to access at country level? What are the reasons for that? 
_______________________________________________________________________________ 
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6. How are the situation of access now in 2017? Do you think it was improved/not from 10 years 
ago? Why is that? 
_______________________________________________________________________________ 
 




8. What do you think is particular for VL drugs access as compared to other NTDs, or even to 
other essential medicines? 
_______________________________________________________________________________ 
 
9. What are your thoughts on integrating VL supply with the public procurement system? (What 




10. Research suggest different supply improvement such as technology use, different distribution 
systems, outsourcing – what are your thoughts about the different options?  
__________________________________________________________________________________________________________ 
 




12. What do you think are the most important actions to be taken at national level (can give 




13. Specifically, for rK39 RDT, in your opinion, what are the most important access barriers? 
_______________________________________________________________________________ 
 
14. Is there any examples of good practices that you thought might be applicable for VL? 
_______________________________________________________________________________ 
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SUPPLEMENTARY INFORMATION 1B 
Information sheet 
Access to visceral leishmaniasis (VL) drugs in Africa – barriers and facilitators 
 
Background:  
The Institute of Tropical Medicine, Antwerp (ITM) is conducting a study, partnering with MSF and 
others, to investigate access barriers to quality drugs to treat visceral leishmaniasis (VL) in 
eastern Africa region. This study aims to analyse the different factors affecting access to these life-
saving medicines, from global and/or regional perspective, in order to enhance access to these 
drugs. Information will be collected for the following products: 
1. Sodium stibogluconate (SSG) - generic 
2. Paromomycin 
3. Liposomal amphotericin B (AmBisome®) 
4. Additional: meglumine antimoniate (Glucantime®), Pentostam® (SSG from GSK) 
5. Additional: rK39 RDT 
 
Interview description: 
All partners or stakeholders involved in the access to VL drugs in countries in east Africa, 
including those providing support (financial or otherwise) to the procurement and distribution 
of VL medicines (and diagnostics). We have selected your organisation and approached you to 
assist in this assessment by providing information (and your expert opinion) on any of the above 
products.  
With your consent, the interview will be recorded, and we will use a semi-structured 
questionnaire in which some information will be noted down. It should take 60 minutes of your 
time.  
Confidentiality and information security 
Participation in this study is completely voluntary and you may withdraw at any time without 
prejudice of negative consequences. All information will be kept secured and confidential. The 
study team will have access to the information arising from this interview. Information which 
could potentially identify participants will not be published without the participants’ consent, nor 
disclosed outside of the study team.  






Institute of Tropical Medicine | 155 Nationalestraat, 2000 Antwerpen | Belgium 
Ph +32 487 72 60 48 | Email: tsunyoto@itg.be | Skype: temmy.sunyoto 
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Semi-structured questionnaire for interviews 
Barriers to effective supply of quality VL drugs and diagnostics in Africa 
 
Name of partner/organisation: ____________________________ 
Name of country: ____________________________ 




Name of interviewer: ____________________________ 
 
Question guides 




2. Who supplies the medicines used to treat VL ? 
 National programme 





3. Which among the VL medicines (and diagnostics) below that are available in your country? 








     
Liposomal 
amphotericin B 
     
Meglumine 
antimoniate 
     
Sodium 
stibogluconate 
     
Miltefosine 50 
mg/tablet 
     
Miltefosine 10 
mg/tablet 
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Paromomycin      
Pentamidine       
Other......      
Other.......      
 
4. Were there donations of drugs for leishmaniasis in 2015 or 2016 (by WHO, pharmaceutical 




5. If yes, please specify the donor and which medicine and its quantities if possible by giving the 
numbers in the smallest unit (vials, tablets): 
Donor Name of drug + manufacturer Quantity (vials, tablets)  
   
   
   
   
 
 
6. Are drugs for leishmaniasis sold in the private sector?  
In regulated pharmacies:  
  Yes/No/Don’t know 
In unregulated drug markets/by drug vendors:  
  Yes/No/Don’t know 
 




Follow up questions/to elaborate more on what is mentioned): 
4 a. Why is so difficult? (e.g. forecasting the demand, …………as per the answer) 
__________________________________________________________________________________________________________ 
 
8. What is the process to procure VL diagnostic (rK39 RDT)? 
__________________________________________________________________________________________________________ 
 
9. What do you think are the difficulties to effective supply of VL drugs and diagnostics? What 
are the reasons for that? 
_______________________________________________________________________________ 
Prompt (tick if appropriate) 
□ No treatment is offered in the public sector.  
□There is no leishmaniasis control programme.  
□Treatment is only offered at advanced health care levels and not at primary care level. 
□There is no money to roll out the existing leishmaniasis control programme.  
□ There is no continuous supply of drugs at public health facilities.  
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 Comments: ________________________________________________________________________________________ 
□ Drugs/diagnosis offered in public health facilities are not effective. 
 Reason: ____________________________________________________________________________________________ 
□ Patients are too poor to pay for treatment which is not offered for free in public health 
facilities. 
□ There is a lack of trained human resources for treating leishmaniasis. 
□ Patients live in very remote areas with no health facilities and no transport. 
□ Transport to health facilities exists but patients can’t afford it.  
□ Patients suffer economical catastrophe due to days of missed work when they spend time 
away from home in order to receive treatment.  
□ Patients do not seek treatment in time due to certain cultural beliefs or a lack of awareness 
of the serious nature of the disease. 
□ There is gender inequality in seeking treatment. 
□ Patients seek substandard private care or care from traditional healers before reporting to 
health facilities. 
 Comments: ________________________________________________________________________________________ 
□ Certain groups of patients have no access to the public health system (refugees, returnee 
camps, tribal regions).  
 Comments: ________________________________________________________________________________________ 
□ Other:________________________________________________________________________________________________ 
 








12. What do you think is particular for VL drugs access as compared to other NTDs, or even to 
other essential medicines? 
_______________________________________________________________________________ 
 
13. What are your thoughts on integrating VL supply with the public procurement system? (What 




14. Research suggest different supply improvement such as technology use, different distribution 
systems, outsourcing – what are your thoughts about the different options?  
__________________________________________________________________________________________________________ 
 





  Supply chain side (manufacturing, selection/forecasting, procurement, distribution 
and delivery) 
Health system side (legislation, coordination, communication, financing) 
Multilateral 
organisation 
- Supply is not the role of WHO, but when there is nobody else - the Ministry doesn’t do 
something or does not procure those medicines and there is no any other partner. 
Without countries’ request though, the HQ cannot do much. 
- The role of WHO is actually to make the programmes in the countries to speak to each 
other and coordinate their needs.  
- There is a gap between policy and reality, which can be frustrated to all sides 
-  “My opinion is that the word ‘integrated’ does not have a room here. Because what we 
need to do is to stop the neglect of those diseases. See, a national medicine system in a 
country, is the national essential medicine list, right? So, this by itself is to cover the 
essential needs of that given country. So, integrated, well it’s the national system, but 
my point is why do those countries have deliberately excluded NTDs from that service? 
So, who decided to exclude our medicines, the leishmaniasis medicines, from the list? 
Because if it’s not in the national medicine list, then everything gets impossible or 
difficult, because it’s not that we should integrate. We should be in the place where we 
must be, so the abnormal thing is to have it excluded. Because then it’s in a corner, 
nobody orders, nobody follows and so on.” 
- WHO depends on external funding, while trying not to duplicate or compete 
with others. Fund use is not very flexible and WHO ready to chip in the supply 
chain when neither MoH nor other agencies can take over.  
- There are some people in WHO who are field-oriented, there should be more 
trust to WHO 
- Country should step up and not neglect their VL patients 
- Capacity in-country should be strengthened as much as possible so dependence 
on external people can be reduced 
- Partnership is crucial among all the involved stakeholders 
- The higher level politicians need to commit, just like in Asia 
- Not all the countries have funding for VL because it’s not a priority disease, and 
affect neglected population so no provisions to give as such. 
 - Level of commitment of people is important, and this is not the case for NTDs 
- There are only very limited resources, and this is linked to the neglect, the 
focal geography plays a role as well 
Donor  
- There have been stock outs of all drugs, over time PM and SSG and also some rapid 
diagnostic test. In Ethiopia in 2017, there had been a problem with a manufacturer of 
rK39. 
- Stock out problem can be due to manufacturing problems, or other bottlenecks such as 
forecasting the needs, which obviously a problem with supply.  
-  There are stock outs due to unexpected emergencies, but also due to the issue of the 
one-source suppliers. Either that they could not finish and get the batch in time, the 
production batch was later than promised and anticipated or that quality issues with a 




- Lack of transparency and logic behind funder (e.g. UK-Aid) decisions, e.g. how 
to utilise the pot of money for VL or NTD in general, operating in Sudan, etc. 
- Various donors involved in supply chain strengthening (e.g. Ethiopia) and 
requires streamlining and consolidation, clear strategy going forwards 
- Vertical approached by NGOs like MSF may be best for patients, but it means 
their presence is needed forever, there is a need for more country level capacity 
building 
- “WHO is not natural leader everywhere’ – country office can hire many staff 
but inefficient and there has been some disappointment over specific activities 
performance.  
- Stock out can be due to communication problem where the drugs were actually 
in the country already, but the Ministry of Health had not released them or no 
communications  
 
- A regional programme for leishmaniasis with regional strategy at a ministerial 
level, like the Asian agreement on elimination.  
- Sometimes things depend very much on the people involved  
- There are sometimes in-country dynamics between institutions and/or between 
people which can complicate this smooth functioning of supply chain of VL 
medicines and diagnostics  
NGOs  - Timely reports are crucial, because procurement is done at the beginning of the project 
and updated regularly, estimate is based on, for example, the number of people tested 
last year and the year before. There was a shortage once (in Turkana), due to the lack of 
communication at the beginning 
- When there is shortage, the buffer stock was not quick enough to cover that, but also due 
to the rainy season it was impossible to land planes in the targeted areas 
- “Yes. So those are the stock outs due to unexpected emergencies, but we've also had real 
problems with the issue of the one-source suppliers that have problems. Either that they 
could not finish and get the batch in time, the production batch was later than promised 
and anticipated or that quality issues with a batch. That is the whole problem with the 
single supplier issue.” 
- Who will take the risk of keeping a stock when no one wants to order? The problem also 
is about the bill, who is going to pay the bill? 
- “Now what we see is that WHO has to do their own procurement, they cannot rely on 
IDA, they have to go directly to the manufactures because they have the rule apparently 
internally that will not allow them to go to a distributer. So, this is already removing a 
major stakeholder in the procurement, but if we could maybe better plan our orders that 
should not be so much of an issue. Both manufactures should be able to see what has 
been the order of WHO for the last couple of years. Then you have IDA, IDA was or is 
doing the procurement for DNDi. At some point these two were supposed to join and 
again the exact reasons why we didn't join at the time I'm not sure about. I know that we 
are a little bit like WHO, we like to procure directly from the manufacturer. We don't 
have to rely on IDA as such. Even though I think that we're now ready to get back to the 
table, because clearly with a decision we took in 2014 or 2015 was not the best one, 
because we lost a lot of money and we lost a lot of stock that we couldn't use. “ (MSF) 
- KalaCORE programme will end in March 2019 and there has been progress, 
but discussions still ongoing on what needs to be done by the national 
programmes. The fear is that without external funding, control will collapse 
and go back to how it was.  
- Very unclear situation once the KalaCORE ends, who will buy the 
medicines? Sustainability is clearly a major issue, between actors we can 
coordinate but it is far from ideal 
- Lack of awareness and varied capacity between counties endemic of VL 
- NGOs need to coordinate always, like in Kenya, (FIND) has strategy to 
improve access to diagnosis, through an agreement with the DNDi and with 
WHO or whoever take the responsibility of making drugs accessible in these 
counties, whenever they are necessary. 
- “The main countries where we have activities are Sudan, Ethiopia, Kenya 
and Uganda and for each of these countries we have partners who are the 
ones implementing the research, but in order for us to be able to implement 
the research we have also a component of capacity building and even when 
we don't have clinical trial going on, we have to maintain minimal structure 
in this clinical trial site. This means that we are also supporting sides for the 
routine treatment of viscera leishmaniasis in the region.” (DNDi) 
- Changing regulations are not easy to follow and there is no real interests 
from the manufacturers to do registration 
- “For diagnostic tests for leishmaniasis, the total shelf life is 14 months and 
according to the regulation of FMHACA when they arrive at port of 
entrance, they should have at least 50% remaining shelf life.” (Ethiopia) 
- “I think that Gilead, did not do it for patients with kala-azar, but more 
because they see the market opportunities with HIV-patients with 
 
 
- Agreement with manufacturers and also in regard to donation needs to be more correct, 
with condition to guarantee access in the long term, for example by engaging in 
registration… the agreement should not be shortsighted.  
- It's 1 thing to have the donation, but we often see that the donation is not enough or that 
the donation needs to pave the way for the future. I don't know if this donation, I mean 
at the end of the day the NTD department is funded by Gilead at the moment. I don't 
think that they have that their hands are so tight. I'm not saying that, but I just ... I'm not 
saying it's that easy, I'm just saying to the contrary, but as we are more and more asked 
to sign this kind of agreements with manufactures, if we are not more careful, they are 
going to put a lot of constraints on us and it would really shrink our activities. 
  
Cryptococcus meningitis but still, it could benefit so we need to sell that 
wave and benefit from as much as we can from that. And then we need to 
push countries that are affected by kala-azar to join this collaborative 
registration procedure so that they can also register faster.  
- It was a great initiative to have ERP mechanism in order to have a quality 
access to a quality product, but there remains no market incentive behind it, 
so manufactures will not be inclined to continue to provide information and 
update their manufacturing standards and also it wasn't really advertised or 
shared or communicated 
- Without coordination, money and time are lost 




 - It’s difficult without forward planning nor predictions and there is stock rupture. Pooled 
procurement is ideal but sometimes people are not completely open about that. There are 
issues of trust and communication.  
-Each drug is challenging, and people need strategy to deal with them. “Gilead is difficult, 
but in the end,  we will manage but for me, Gland Pharma is much more unclear on what is 
going to happen. Albert David isn’t such a difficult manufacturer “ 
-Definitely, IDA has been busy with these manufacturers from the beginning of the 90s, and 
there's no other organisation with so much experience with SSG.  
- “For NTD, it’s the same system, only then we do more strategic meetings on what products 
we keep in our stock. It’s an effort we do especially for the regulatory affairs, then I come in 
and interfere a little bit to get it in the right direction… And of course, we have a policy 
internal about what kind of focus areas and which type of neglected diseases we would like 
to give some extra attention” 
- There is not a better preparedness in case of a large outbreak as in 2014, “When quite quickly 
all our stock were depleted, and MSF had to buy large quantities directly from the 
manufacturer and Gland Pharma, being in that day, a very unreliable partner and made it very 
difficult.” 
- Costs are increasing, because there are so many regulatory requirements every time so there, 
or a change like in Kenya, suddenly "Oh, now registration is not needed anymore". But still 
there is a need of country representative to navigate through different things, and there are 
regulations that you can only find out when you start a registration. Sometimes they are easy, 
-“The problem then and all the time is to try to establish who’s going to be doing 
what … I feel like people always try to do something, but it’s not very 
coordinated. It’s not in the open and clear, and that’s what I’m still missing a little 
bit.” 
- All the parties and stakeholders need to do it better than this, even if they have 
specific purposes like research, because we are there to serve the people and to 
get better access if everyone put the experience in that. 
- “Relations between organisations isn’t always easy, but there are possible 
solution. Better to have one party doing whole stock keeping, who has a more 
global view on the situation. IDA, for years, has been the leading supplier with 
good contacts with the current manufacturers. For me, again with the experience 
I have with IDA, they're always willing to negotiate and come to a very good 
solution. They take action. I think, you should sort this out instead of wanting to 
do it yourself. But again, our experience with IDA is positive and I can't say that 
the French or MSF Logistique think that way. So, if you look at the role of WHO, 
which of course is difficult, because I know that in the past WHO and IDA used 
to cooperate and now because... As I understood, the administrative system of 
WHO with regard to procurement has changed and they're not allowed to work 
in the same way with IDA, so you have all kinds of matters influencing the 
solution of what, again in my eyes, is a very simple .... I mean, we're talking only 
about a few drugs. We're talking about a disease that is being well-monitored, so 
 
but sometimes they can be very difficult, and they can get a little bit annoyed if they want all 
kind of things, leaflets and changes.  
- If there are contradictions between all these countries for the requirements of one product, 
then it becomes very difficult. 
- Harmonisation of the regulation is needed. Of course, every country differs, but… 
 
  
you could react quite quickly if you had a centralised approach. And the moment 
you chose not to do that, that's the core issue. You fragment the demand and you 
fragment the supply and that makes it very difficult, and again, it's something we 
cause ourselves. If for some reason we're not wise enough to step out of whatever 
problem we have and look for a solution. Again, I'm not naive, but in this case,  I 
find it very difficult to accept that you cannot find a supply solution here.” 
- “For registration, somebody has to be the owner of the dossier, add the 
stability data and pay for new updates stabilising and continue the stability. 
Then you can out contract it to any manufacturer, that is not the problem. 
The formula of the contract, that’s possible of course, but then you should 
have somebody who owns the intellectual property of the manufacturing 
process and update a dossier every time and do the registration, the 
submissions … And that’s also still quite costly, these kinds of things. IDA 
very often has people telling them: “Oh do the registration”. And then they 
don’t realise that there’s quite some effort and capacity needed for that.” 
-  
Manufacturer - Availability and accessibility is critical, especially the capacity of the different partners 
to provide the forecasts.  
- « Now the major problem they have, talking about the WHO, PAHO, and others, is that 
they provide this to governments. Governments... The Ministry of Health its intentions 
to buy is in terms of volumes, but those who give the forecasts of intentions to buy in 
terms of volumes, are not the financial guys. A lot of intentions to buy do not materialise, 
because they don’t have the money when they go back to double check. So, whenever 
we have a tentative forecast, we know it’s not going to be correct and the production 
takes a lot of time and is costly so it’s hard to keep a big amount and it expires gradually 
because the orders are not coming. So, that is our main challenge at our level. » 
- SSG has a dedicated facility, so it will be there as long as needed 
- For PM the amount is 65-70,000 ampoules per batch, and the company is not making 
any profit to that, this is cost to produce, with very negligible margin, that has been fixed 
since 10 years... and since then everything has gone up and they take it as CSR 
(Corporate Social Responsibility) initiative 
- Production will continue as long as there is order, and capacity can even be increased  
- “Pre-qualifications process is sometimes seen as looking into destination in 
the European market nowadays. For SSG, they asked a lot, a lot of data, on 
identification of all kind of product, because there is perception it is not a 
very well characterised product and you have to investigate further, and the 
whole thing is just process, I don’t see AD as culpability, but I don’t know 
if they’d do it if they know the product is good.” 
- “Registration of the drugs in the different countries may have lapsed, 
because the last owners really pursue this, as they never get orders from the 
private sector and when the orders are coming from the public sector there’s 
always an agreement from the government to get it in. So, a registration 
process, for example in Brazil, for a normal drug takes 5 years. In many 
countries it takes 3 years. It’s costly in terms of work, because you have to 
follow up on it permanently, you have to add new documents and you have 
to do this and then the other. So even us at this point in time, because we 
never have all private orders, we are not even looking into re-establishing 
the registration. “ 
 
 
- It is simple: 60,000 ampoules, 1,5 $ each so total is 100,000 so not that much. So, anyone 
can do this and buy supply for one batch and then distribute to whoever will buy from 
them. Irregularity of the order is a problem. The low margin also an issue as it means 
keeping stock is like blocking money, resources. 
- Sustained demand is the key issue 
- Price is agreed before, and Knight has policy of different prices when it is a full batch 
or more than a full batch. What happens when we do a full batch, because of the 
regulation we have to do regular analysis on the quality of the product. You rate the time 
and date of expiry. Those analyses are very expensive. It increases the cost of the product 
if we sell a batch over a long period of time. Now, if we sell this batch immediately, we 
only have to do the regulatory control of the quality for the time that we have it. If we 
sell it within 6 months, then … Because we don’t have it anymore, we can’t do this 
testing. It’s already in usage, so that way we can offer a different price when the batch 
is sold full. Those prices are already been communicated to WHO, DNDi. 
- “That agreement says also that the price has to be covering the costs plus a margin. That 
agreement was signed, I don’t know how many years ago, but before 2000. And since 
then there has been an increase in costs everywhere. That particular agreement never 
took that specifically in consideration. Now, we were not the signatories of this 
agreement, but it has come to us with the acquisition of the product and what we look at 
is how much it cost us to make and you very well know, regulations on pharmaceutical 
drugs have not reduced the number of controls and checks and quality this and quality 
that and reporting this and reporting that. All the opposites, everything is increasing 
every day, you know. So, considering that the price that was valid 20 years ago is today 
is counter intuitive” 
- Expanding indication is not easy and requires all the trials 
- Donation as a policy is not universally possible for all manufacturers as it is not seen as 
economically sound.  
- “Consistently right now, with the trends we have, the trends are more for producing the 
orders than increasing them. We’re caught into this particular situation.”  
- Regular meeting between Gilead and WHO  
- For this kind of disease with no private market, there definitely a need for 
collaboration 
- The price is about quality, with assumption that lower price is lower quality, 
an analogy made: “ there is already generic manufacturers in India, it’s like 
18K gold versus 24 K gold. If you don’t have money for 24K gold, you 
should be happy with 22 K gold.” 
- Technology transfer is done but nobody is able to make the medicines  
 
MoH - WHO emergency stock is in Geneva, for all the world. “Few years ago, 2014 we had 
shortage for long period for PM, even this time we have problem with PM... that is 
internal logistic in WHO, people who received is not the one responsible, one month 
nobody knows where it is… they say IDA sent it, the logistic received it and keep them 
in the stock not knowing that people are waiting... we are asking for the drug and we 
don’t get them, there was an outcry and somebody remembers oh I received that some 
time ago can you check... and that was three months later.. 
- “Before KalaCORE, there was sometimes no drugs in the country, a national shortage” 
(Sudan) 
- “The health centre may saw only 10 people because after 2 weeks rupture in drugs, so 
nobody came, but the next month they only ordered the same ... that ability to have a 
constant supply also limits their knowledge on the number of cases, because they don't 
record the case that they weren't able to treat” (South Sudan) 
- Microplanning at the health facility level 




- Complexity of the disease, with treatment regimens vary for both visceral and 
cutaneous leishmaniasis and at country level, we lack capacity to manage them, 
these compounds being also neglected, unlike malaria 
- Elimination target brings donor attention, but for country in Africa this is still 
very far thus less attractive for funding 
 - “Regional approach I think indeed it can be easier and the drug can be closer, 
we do this with WHO emergency stock the drugs go to Somalia, South Sudan, 
where forecast is difficult. So perhaps regional approach makes sense. However, 
agreement between countries are needed, a kind of MoU similar like what they 
did in the elimination in India, at least in the region.” 
- Training and supervision of the staff is important 
- There is not enough budget to cover leishmaniasis as one, not separating VL 




- Transporting sample can be a problem, for example for DAT samples, adding delays of 
3 weeks, 1 month. Other places they told the patients to wait after checking for malaria, 
but unclear if or whether they were coming back  
- Geographical access to the areas can be difficult, borrowing from MSF until the 
consignment arrives 
- “Whenever there is a stock amount below the threshold, we run and try to avoid any 
rapture. There are sometimes issue with the expiry or customs, but total rapture is rare” 
- “In 2016, we had that very shortage, especially SSG was out of stock. WHO supply was 
not available; so, we tried to get from Nairobi, but it was very costly and can’t be 
sustained by us’ (local NGO in Somalia) 
- “Yes, there were several stock outs perhaps every 2 or 3 months. Main reason again, 
because it’s not integrated in the system, if it was integrated it was only PFSA who 
distribute it to the health facilities, and would have been better… but the problem was 
it’s kind of orphan drug, it goes through the programme, due to lack of integration, the 
- Capacity of the health facility varies (cold chain, drug administration) 
- Procurement always by external agent, e.g. AmBisome is just with WHO. 
- Referrals very difficult.  
- “Pool procurement, including to align the ordering schedule is something 
that needs to be done, but it's not simple because everybody needs to agree 
... I do think that what happened a couple of years ago is that MSF needed 
urgently some products and could not wait for this pool procurement to be 
set up and that's the reason why they decided to go ahead: they had a big 
need and they just went.”  
- Training is difficult because people changing all the time; the poor 
functioning of the health system definitely is a barrier 
- “Having the integrated system, I do think that was the way forward but then 
you just need to get the people that buy in and get the training and actually 
do it. You need to have a health centre, a health post who has a champion. 
 
 
estimation or quantification is done separately at national task force, we did 
quantification for three years, we made distribution lists based on treatment sites, or 
needs that we thought per site based on case load, and after for every compound, 
antimonial, PM, the tests and this was distributed by the ministry every three months. In 
collaboration with the Regional Health Bureau. So, it means it is not fully integrated in 
the PFSA so sometimes you have the drugs in the Regional Health Bureau, but at the 
health facilities there are no communication and the stock of PFSA at regional level was 
not properly communicated to the programme.” (Ethiopia) 
- Especially like, considered the diagnosis tests for leishmaniasis. This data in total shelf 
life is 14 months and according to the regulation of FMHACA when they arrive at port 
of entrance, they should have at least 50% remaining shelf life.  
-  
If you have one strong person who is willing to drive it, willing to push these 
processes through then I think you can have success, but often that's what 
missing. You have people who don't show up to work, there's a super high 





















Ensuring access to quality care in eastern Africa is challenging. Children often bear the brunt of infectious 









 This thesis aims to improve our understanding on access to leishmaniasis care in the sub-
Saharan African (SSA) region, by documenting availability, affordability, and accessibility of care; 
exploring novel ways of enhancing such care; and providing insights for policy formulation.  
 
THE BURDEN OF LEISHMANIASIS IN EASTERN AFRICA: IMPACT OF CONFLICT AND KNOWLEDGE GAPS  
 Over the past decades, leishmaniasis has obtained unprecedented attention from the 
international community, much in relation to the 2005 regional elimination initiative of visceral 
leishmaniasis (VL) -or kala-azar- in the Indian subcontinent126. Since 2005, global VL cases have 
declined dramatically, but this is not the case in eastern Africa. Countries in this region, namely 
Sudan, South Sudan, Ethiopia, Kenya, Uganda, and Somalia are one of the geographic areas 
hardest hit by VL. Conflicts, displacements, drought and dysfunctional health system are some of 
the determinants of VL in eastern Africa countries.  
 Somalia, the country of focus of Article 1, is the archetypal example of leishmaniasis in a 
‘fragile state,’ whereby availability and accessibility of care face extra challenges. Our work is the 
first published paper about VL in Somalia after a 10-year gap since the last one by Raguenaud et 
al. (2007)127, providing a comprehensive update. Somalia has replaced Bangladesh in the top 
seven high-burden VL countries since 20151,128, with 1400-2700 VL cases estimated per year2. A 
significant number of patients, however, may not reach health centres due to access issues. There 
is limited coverage and quality of leishmaniasis care in the country, with only three centres 
located in the militia-controlled areas. The country depends entirely on WHO for its supply of VL 
drugs and diagnostics.  
 VL in Somalia is not well documented, with only two reports on VL cohorts from endemic 
areas: the first one the above-mentioned study by Raguenaud et al about the MSF centre in 
Huddur (1671 cases in 2004-2006)127 and a 2017 report from three WHO-supported centres in 
Baidoa, Tijeglow and Huddur (3112 cases in 2013-2015)129. These studies reported that more 
than half of the VL patients were children under 5, whose susceptibility was often aggravated by 
poor nutritional status130. Monotherapy with SSG alone continues, as the supply of PM relies on 
DNDi129. The prolonged hospitalisation for treatment affects service uptake, as families have to 
cover travel and food expenses. Nevertheless, there has been progress on several fronts, e.g., on 
surveillance with mapping village level data, implementation of DHIS2129 and intention to assess 
the feasibility of AmBisome® use in 2018131.   
 Our review shows that leishmaniasis remains a neglected disease in Somalia, competing 
with other health priorities and impending catastrophes such as famine threats and cholera 
outbreak132. Would the prolonged conflict setting in Somalia increase the risk of an outbreak in 
the future? We cannot provide a definite answer to that question, but in any case, the mechanisms 
by which conflict exerts an impact on disease outbreaks are challenging to pinpoint. Spiegel et al. 
analysed the overlap between the 30 biggest natural disasters, complex emergencies and 
epidemics over 1995-2004 and concluded that lethal epidemics occur more frequently during 
large-scale complex emergencies133. For leishmaniasis, its association with conflict has been 
demonstrated through a series of factors: people moving to areas with active transmission, the 
weak nutrition status following the displacement, and the lack of access to health services. Based 
on 1995-2010 data, a significant dose-response relationship for leishmaniasis (cutaneous/CL and 
visceral/VL) incidence on increasing levels of conflict and terror was reported134. The odds ratio 
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for CL and VL in country-years with very high levels of conflict-terror were 2.38 (95%CI 1.40-
4.05), and 6.02 (95%CI 2.39-15.15), respectively. The stronger risk for VL is linked to its 
anthroponotic transmission, which corresponds with displacement, crowding, poor housing, 
immune-compromised health status, and increased human-vector interactions. Health system 
deterioration also plays an important role in exacerbating the impact of conflicts.  
 The impact of access breakdown due to conflict is best illustrated during the 1984-1994 
VL outbreak in Western Upper Nile, South Sudan3. Between 1999-2002, only 55% of people can 
access care and close to 91% of deaths were unseen135. Treatment was only started in 1989 in 
Khartoum for the refugees, while aid agencies could only access the epicentre of the outbreak two 
years later. Another epidemic recurred in 2009-2012 with more than 76,000 cases and only in 
2010 the 17 days SSG/PM is rolled out beyond MSF sites4. Responding to the outbreak was 
difficult as most areas are cut-off during the rainy season and the number of people who died 
because they could not reach a treatment centre is unknown. Unfortunately, the conflict 
continues; following a clash in December 2013, tens of thousands of people fled to VL endemic 
areas during the high transmission period (February-May). More than 6000 VL patients were 
treated at MSF-H site in Lankien during a nine-month period, amongst whom 23% were 
categorised as severe136,137.  
 The cyclical epidemic patterns of VL, combined with population displacement and lack of 
access to diagnosis and treatment, create the ‘perfect storm’ conditions for a VL epidemic36. Our 
review on Somalia, therefore, underlines the need for improved preparedness, especially as 
conflict and unrest remain rampant in almost all the endemic countries. In South Sudan, ethnic 
and political tensions persist, and sporadic fighting continues in the areas known to be VL 
endemic such as Greater Upper Nile, the Equatorial provinces and parts of Greater Bahr el Ghazal. 
Despite efforts to revitalise a fragile 2015 peace deal, more than 4 million people have been forced 
to flee their homes, half of whom took refuge in United Nations compounds or neighbouring 
countries138. In Somalia, though the civil war between rival clan warlords is already decades-long, 
the situation remains volatile with flare-ups against the Mogadishu-based federal government 
and ensuing military offensives. The al-Shabaab militants continue to carry out deadly attacks in 
(e.g., Mogadishu bombing that killed 512 people in 2017 and several others in 2019) and outside 
the country (Uganda was attacked in 2010 and Kenya in 2013, 2015 and 2019)139. In 2017, the 
UN estimates 1 million people were newly displaced, bringing the total internally displaced 
persons (IDP) population to 2.1 million. Access to the southern areas remains a challenge along 
with disruptions to supply chains because of insecurity.  
 Other countries in the region are relatively stable, yet with their own woes. Ethiopia only 
lifted its state of emergency in April 2018, after years of widespread protests against government 
policies. In Sudan, low-intensity armed conflicts continue between government forces and armed 
opposition groups in Darfur, Southern Kordofan and Blue Nile states. Recently, Sudan was 
predicted to be on a trajectory towards a health and humanitarian crisis because of the near total 
collapse in governance140. The civil unrest, triggered by high prices of food and essential 
medicines, started in December 2018 in the town of Atbara, located in the high VL burden state 
of Gadarif141. Hospitals have reportedly been attacked and doctors arrested142. Despite the 
eventual Bashir regime fall, the situation is still tense and not fully stabilised as consensus 
between civil society and the military has yet to be reached.  
 Conflict could derail health programme and services, including and perhaps, more 






situation is very difficult. Some lessons have been learned. Decentralisation of care, in the form of 
‘mobile clinics’ in which trained local teams provide VL care, have shown to work in South Sudan4. 
With cross-border population movement, provision of VL diagnosis and care in the refugee camps 
in Uganda and Ethiopia may be justified, including efforts to increase awareness of the health 
workers in areas receiving an influx of people. Based on our findings on Somalia, innovative 
approaches adjusted to the context appear to be important, such as working with the community 
including clan elders and utilise the widespread mobile phone network in rural Somalia to 
encourage care-seeking. Parallelly, efforts to improve coordination in health assistance, ensure 
sufficient funding and reduce the silo-approach of the federal government structure are 
important144. Rejuvenating the country’s capacity, including in research, is imperative in the long 
run and has recently started through Swedish and Somalia universities collaboration145.  
 Our review of Somalia serves as a reminder that tackling leishmaniasis in highly insecure 
context need bold actions. NTD should not be excluded for the health prioritisation and continued 
as moral imperative146. The lack of appropriate diagnostic tools and medicines for the kind of field 
settings in eastern Africa, therefore, needs to be addressed and shall be of note in the advocacy.  
 
KNOWLEDGE GAPS: EPIDEMIOLOGY OF CL AND LEISHMANIASIS SOCIO-ECONOMIC ASPECTS 
 Knowing the magnitude of the problem is the first step in addressing it, although assessing 
the real burden of leishmaniasis remains complex56. Article 2 and Article 3 focused on areas 
where considerable knowledge gaps existed. In both papers, we adopted the methodological 
approach of a systematic review of the evidence.  
 Cutaneous leishmaniasis or CL has been given lesser priority by countries and the 
international community due to its non-fatal nature147. Nevertheless, CL occurs across vast 
geographical areas, and the psychosocial burden it entails has recently gained recognition148. 
With the ongoing war in Syria, an increased number of cases have been reported149,150, not to 
mention other conflict-related CL outbreaks in Afghanistan, Iraq, and Pakistan in the last 
decade151,152. Epidemics of CL has also been reported following a major earthquake in Bam, Iran, 
due to activation of several risk factors153,154. L. tropica, with its anthroponotic transmission, 
flourishes in urban settings, while the zoonotic L. major is considered the main cause in the rural 
areas of Africa. Some VL high burden countries in eastern Africa are also prevalent for CL, most 
notably Sudan. The intriguing L. aethiopica, confined to the Ethiopian highlands and a pocket in 
Kenya, causes up to 50,000 cases per year. The lesions commonly evolve to diffuse CL or 
mucocutaneous forms and are notoriously difficult to treat155,156. Several countries in western 
Africa are known to be endemic for CL, but with less intensity and as a consequence, the problem 
is less documented. In summary, the epidemiological burden in sub-Saharan Africa (SSA) was 
largely unknown. 
 Our systematic review covered all published evidence on CL since the colonial times and 
included 54 papers. These papers showed high methodological variability, so caution is needed 
when comparing results. A number of studies evaluated infection prevalence. The Leishmanin 
Skin Test (LST) was used in community surveys to explore reported foci in Senegal, Guinea, and 
Mali in the 1980s, with prevalence rates ranging from 5-61%. While LST can only prove exposure 
to the parasite, other studies use hospital records or active screening to report CL 
prevalence/incidence of active lesions and the scars. One-third of the studies were case series 
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and therefore do not reflect the true burden, though they do provide some insight on the clinical 
features and co-infection with HIV, an emerging threat157,158. Passive surveillance at facility level 
further reflects data paucity at country level, and only during outbreak settings (such as reported 
from Ethiopia, Sudan, Ghana, and Burkina Faso) that leishmaniasis gained attention. Studies 
reported the causative species poorly. 
 CL is generally treated using the same medicines as VL. Therefore, a high number of CL 
cases stresses the supply lines for both diseases. The current lack of appropriate diagnostic and 
treatment tools for CL seems to contribute to the lack of quality data from SSA. Underreporting 
of CL cases is very common as diagnostic methods are not widely available. Moreover, the lack of 
effective treatment of active lesions and scars leads patients to rely on self-treatment, traditional 
and folk remedies, which are not captured by the surveillance systems. Evidence are scarce: the 
2017 Cochrane review on interventions for Old World Leishmaniasis concluded that there were 
insufficient studies to be included and eventually could only reported the certainty of evidence 
for two identified comparison (oral itraconazole and paromomycin ointment) for L. tropica, 
which was very low71. Guidance on standardisation of methods for the conduct and analysis of 
clinical trials of CL have been proposed159,160, but a new breakthrough for CL is currently not 
foreseeable in the near future.  
 We proposed in our study to improve surveillance, at the very least to mitigate outbreak 
risks. One emerging policy approach is to integrate CL with other NTDs affecting the skin such as 
Buruli ulcer, leprosy, mycetoma, yaws, lymphatic filariasis, and onchocerciasis. With adequate 
training, local health workers can identify multiple conditions in a single visit, either at the 
community level or in schools161. An integrated approach to skin NTDs is expected to increase the 
coverage and cost-effectiveness of interventions162. Advocacy to obtain political support as well 
as resources from stakeholders for this approach is important. Acknowledging the importance of 
each of these conditions in terms of burden, and the limited resources available to tackle each 
vertically, the integrated approach may have the potential to advance the control efforts of this 
diverse group of diseases. 
 A second knowledge gap that we attempted to address is the socio-economic burden of 
leishmaniasis (in Article 3). Leishmaniasis is intricately linked with poverty163, but its economic 
impact on the patients and their households is more difficult to ascertain. Our study 
systematically identified and reviewed all cost-of-illness (COI) studies on leishmaniasis across 
the world. From the 14 included studies, there is only one from eastern Africa (Sudan), while a 
majority (n=11) are from India, Nepal, and Bangladesh. All included papers focused on VL except 
one (PKDL) and no COI studies were found for CL or MCL. Costing studies from a health system 
perspective are even more rare and as shown by Brazil, mainly used the top-down approach 
based on national insurance data, which are non-existent in VL endemic countries in Asia and 
Africa to date.  
 We reported a substantial socioeconomic burden due to a visceral leishmaniasis episode 
(ranging between 11-57% annual households’ income), a burden even more pronounced when 
there is household clustering with more than one VL patient per family. The patients’ pathways 
to eventually reach care varied according to context, but all studies demonstrated that patient 
and doctor delay clearly augmented the costs incurred. While standardizing the costs to US$2016 
for ease of comparison, the direct cost of a VL episode was $760 in Sudan70 , $189 in India85 and 
$76 in Nepal19. Although the VL diagnosis and treatment are provided for free in the public sector, 






Sudan, where transport and food costs remain substantial. This is probably similar in other rural 
contexts in eastern Africa. Indirect costs in terms of productivity loss are detrimental in the long 
run and coping strategies to avoid catastrophic health expenditure are commonly reported. This 
profound impact on household wealth was one of the main arguments WHO used to plead for 
investment in control efforts for leishmaniasis116.  
 Nonetheless, the data on the economic dimension of VL and its control are scanty. Only 
when all economic evidence is put together can we see the gaps: firstly, from the methodological 
point of view – COI studies are cross-sectional in nature and may use different category of costs, 
making comparisons difficult. The current cost evidence for leishmaniasis also is outdated as 
treatment regimens changed, such as the shift to single-dose AmBisome® in the Indian 
subcontinent and a shorter duration (17 days) regimen of PM and SSG in Africa. Only one study 
reported a relatively recent data on economic impact of CL patients (2013-2016) from Sri 
Lanka164 . Certainly, there should be more economic evaluations to better inform policymakers. 
But perhaps the main recommendation we can make on the basis of current findings is that 
removing access barriers during the care-seeking process and reducing patient and doctor delay 
will have a major mitigating effect on the vicious cycle of poverty that VL induces. 
 
UPSTREAM DIMENSION OF ACCESS: BARRIERS IN THE R&D FOR LEISHMANIASIS AS NTD  
 As the previous section demonstrates, the lack of appropriate tools is one of the vital 
barriers to tackle leishmaniasis in eastern Africa. Optimising the existing diagnostic tests and 
medicines is important, as the outcome of the current R&D pipeline is still uncertain165. All 
countries in eastern Africa base their national guidelines on the same therapeutic arsenal: SSG, 
PM and LAMB (AmBisome®); unfortunately, without different drug effectiveness as in the Indian 
subcontinent. Innovation is therefore critical, also in the light of the HIV-VL co-infection problem 
in the region; where the therapeutic needs are even more pressing.  
 In Article 4 of this thesis, we made a case study of MF development and post-marketing 
access, as it illustrates well the challenges in the domain of R&D for NTDs. The lessons learned 
are undoubtedly important for the future products and also relevant for access to medicines in 
general.  
  Miltefosine (MF) as the only oral drug for leishmaniasis underpinned the big hope to 
overcome the limitation of injectable drugs. Though discovered serendipitously while being an 
anticancer drug candidate, MF (Impavido®) was expected to be the breakthrough in 
leishmaniasis therapy. Unfortunately, its potential was not fully realised due to various access 
issues. MF reached the milestone of registration in 2002, only 7 years after the public-private 
partnership (PPP) sponsoring it was created. The company signed an agreement with WHO/TDR 
motivated by the market opportunity offered by the high burden countries (e.g. India) aiming for 
elimination166. For a mid-sized company -like Zentaris at that time- the attractive features of being 
part of a PPP was the availability of public assistance, including substantial in-kind public input 
and expertise from WHO/TDR167, and trials support from the Indian public research groups. 
Registration in India was promptly achieved, but negotiations for the WHO-agreed price (for the 
public/NGO market, aimed at US$60 per course) took longer than expected. As the public market 
was not accessible by the company, Impavido® was launched first in the Indian private market 
at the price of US $150 per treatment course  ̶ made it out of reach for the poorer patients who 
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need it. The partnership’s failure in the rollout phase of the drug persisted, along with changes in 
the owners of MF and problematic procurement; resulting in shortages and continued use of 
already resistant antimonials some years beyond designation of MF as first-line regimen for VL168.  
 In brief, the rights of MF was exchanged 4 times and the current company, Knights 
Therapeutics, registered the drug in the US and obtained the Priority Review Voucher (PRV) in 
2014. The PRV is one of the ‘pull’ incentives designed to stimulate private companies to develop 
drugs for tropical diseases, awarded when the drug is approved by the U.S. Food and Drug 
Administration (FDA). The voucher can then be used to reduce FDA review time by about 4 
months for another drug (thus gaining market advantage). This voucher can either be used by the 
same company or sold to a third-party. The PRV for MF was sold to the company Gilead for US$ 
125 million, earning Knights a significant windfall – albeit for a product it never helped develop.  
 In summary, the patent-based, value-maximising model of drug discovery and 
development is not geared towards diseases of poverty, as we described. It has become 
increasingly accepted that the pharmaceutical industry, especially the big multinational pharma 
companies, will not invest on R&D for diseases without viable market, even if governments would 
make advance market commitments, as these markets are simply too small and not lucrative. 
Public intervention and regulation is therefore needed, and public-private development 
partnerships have proven their value. Based on our analysis we identified several key points 
worth noting for such product development partnership (PDP). One, more concrete and binding 
conditionality for access should be included in the PDP partners’ agreement. Ensuring sufficient 
safeguards for affordable public access is crucial. Similar calls have also been advocated for 
donation from the pharmaceutical companies, which is a laudable gesture, but often left the public 
at the mercy of the donating company169,170. Access, including through donation or tiered pricing, 
and should be backed by enabling regulatory environment, and with sustainability in mind98.  
 Since its creation, a PRV has been awarded to 8 drugs with tropical disease indication. The 
2014 PRV for MF for leishmaniasis generated calls to the US Congress to amend the drawbacks of 
the scheme171,172. First, to truly reward novelty drugs, not old ones that have been used outside 
the US for some time (which was the case for MF and three other PRV drugs: artemether-
lumefantrine and bedaquiline, and the 2019 awardee triclabendazole). Demonstration of the 
registering company’s involvement in the drug development is also desirable. Second, the PRV 
awardee should do better in ensuring access109,173. Albeit no refinement has taken place for the 
PRV scheme so far, there has been an encouraging development. In 2017-2018, three drugs which 
received a PRV were registered or at least supported by a PDP: benznidazole for Chagas disease 
(Chemo Group/DnDi)174, moxidectin for onchocerciasis (Medicine Development for Global 
Health, with WHO/TDR)175 and tafenoquine for P. vivax malaria (Medicines-Malaria Venture and 
Glaxo Smith Kline)176. The real impact of the PRV in stimulating R&D for tropical disease is still 
inconclusive, especially with the decline in PRV value to currently US$80 million (from an average 
price in 2016 of US$200 million)177.  
 Coming back to our last point on MF, we iterated the importance of safeguards for public 
affordability. High price of medicines has increasingly become a concern even in high-income 
countries, e.g. for cancer medicines178. From the industry perspective, the traditional justification 
of high drug pricing is to recoup the R&D cost or more recently the ‘value-based pricing’ (i.e. the 
costs inherent to the value of drugs for avoiding future cost of more complex, invasive therapy or 
procedures)179. However, analysis has suggested that it is difficult to accurately estimate the cost 






methods used180,181. What we need to emphasise is the significance of public sector contributions 
to the R&D of medicines. These include funding of basic science research, physical research 
infrastructure, education of medical research workforces and even incentivizing R&D through tax 
credits or reductions. For NTDs, the 2017 G-Finder survey reported that public investment 
accounts to 30-65% of the global investment for R&D182. Such public-sector investment has led 
directly to the discovery and development of leishmaniasis medicines such as MF and PM. 
Therefore, a claim to recover the full costs of R&D by setting high prices for medicines developed 
with significant involvement of the public sector seems unfair. Medicines for NTDs should be 
developed with the public health commitment at the outset, as the patients should not be 
expected to pay.  
 In this regard, there have been considerable efforts to improve the R&D system in recent 
years in the interest of the public. With skyrocketing price of medicines, the attention on this issue 
is spreading beyond low (and middle) income countries. Initiatives aiming for better global 
governance on R&D were formed, including (but not limited to): the WHO Consultative Expert 
Working Group on Research and Development: Financing and Coordination (CEWG) in 2012183, 
the United Nations Secretary-General’s High-Level Panel on Access to Medicines in 2015184, and 
more recently, the WHO/TDR project on Health Product Research and Development Fund: a 
Proposal for Financing and Operation185. Other collaborative efforts are in place, mainly for 
mapping different facets of R&D, for example the G-FINDER survey and database that reports the 
global investment in R&D for neglected diseases106, the new Global Observatory on Health R&D 
hosted by WHO and the TDR Portfolio-to-Impact R&D modelling tool to analyse the health 
product pipeline of the poverty-related neglected diseases186. Furthermore, there is evidence that 
the use of TRIPS (Trade-Related Aspects of Intellectual Property Rights) flexibilities as measures 
to ensure access to medicines for all was more frequent than previously thought187. A real 
convergence towards a global treaty and governance for R&D may still be a wishful thinking188, 
but nevertheless the critical mass is forging189. 
 In the last decade, leishmaniasis R&D benefitted from steady global funding, with an 
annual average around $40m per year182, with almost two-thirds for basic research. High-income 
countries and multilateral donors made up the most budget (69%), followed by philanthropy 
(20%) and industry (11%). Leishmaniasis control is in dire need of a vaccine, as well as more 
effective, oral drug formulations and better diagnostics that can detect early-stage disease. At 
least one vaccine candidate in clinical development is undergoing evaluation for prophylactic and 
therapeutic indications190. A topical formulation of an existing drug (amphotericin B) is currently 
in clinical trials for the treatment of cutaneous leishmaniasis191. A phase III trial for combination 
therapy MF/PM for VL is also underway in Ethiopia, Kenya, Sudan and Uganda192. Several projects 
to improve diagnostics for resource-limited settings include optimizing an antigen test (urine-
based),, a LAMP-based test for VL and CL193, and validation of rK28 RDT in the frame of 
AfriKADIA194. In terms of new molecules, there are two pre-clinical compounds that enter clinical 
development this year (DNDi 6148 oxaborole and 01690 nitroimidazole class)9.  
 With the rapidly changing landscape for R&D for NTDs, our work should serve as 
compelling evidence on the importance of post-marketing access. The MF case study 
demonstrated the complexity of ensuring such access, but also that this is indispensable for the 
patients affected by leishmaniasis. Developing new tools for the disease will be useless if its 
affordability, availability, and quality is not optimal.  
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ACCESS DOWNSTREAM: BARRIERS AT HEALTH SYSTEM AND COMMUNITY LEVELS 
 Once the products are defined, next phase of access begins. When access is translated to 
timely use of necessary health product/technology, what comes to mind is the process through 
which the products finally reach the patients. We have approached the issue by focusing on the 
access barriers occurring at two levels: the supply chain (within the national health system) and 
the community. Understanding what these barriers were is critical in proving our hypothesis of 
the access inadequacy. We showed that, while adequate access implies an uninterrupted supply 
of diagnostics and medicine, in reality many barriers exist, and they may deter care-seeking 
process by the patients.  
 In both works (Article 5 and Article 6), we employed qualitative research methods to 
gain a rich in-depth understanding regarding the actual barriers in the field to diagnosis and 
treatment of VL. Article 5 highlights that the robustness of the health system and health service 
organisation in each country is paramount. The country capacity serves , as mediator between 
challenges at international (see access upstream section) and national level in ensuring effective 
supply of commodities for health. In Article 6, we engaged with the community living in Gadarif 
state of Sudan, which has been a hotspot of VL since decades. How exactly do former patients 
perceive the care they received, and what are the opinions of community members and leaders 
or the health care workers? What stood in the way to utilise the available health services, and 
have these barriers changed? Article 5 and 6 are interrelated and provide insights into a 
complexity of access in Sudan and beyond. 
 Disruption of supply is common in eastern Africa countries. One example is the 
unprecedented demand related to VL outbreaks in South Sudan in 2012-2014 causing ruptures 
of PM, and procurement difficulties of RDTs necessitating lending and borrowing among health 
actors. Causes of shortages are complex and involve both supply and demand factors, and existing 
data on these issues are not robust. Therefore, we explored the views of purposively selected key 
informants, representing both the demand side (i.e. national programme or ministry of health, 
implementing NGOs and international organisation) and the supply side (procurement agencies 
and manufacturers). This is the first comprehensive study involving key stakeholders- focusing 
on leishmaniasis commodities supply in eastern Africa.   
 The key barriers to effective supply of leishmaniasis medicines and diagnostics that they 
identified were related to 1) selection and manufacture (issues of single producer, quality 
concern, …) 2) poor forecasting (issues of unreliable data, fluctuation, ...); 3) procurement 
(complex process, parallel system) and 4) distribution and delivery (logistical challenges,). These 
were directly influenced by the gaps in the related health system building blocks – coordination 
and communication, financing mechanisms and regulatory environment. The manufacturers’ 
perspective was evidently informed by their economic considerations (questioning why the 
burden estimates of VL do not translate linearly to orders and a general reluctance to register 
their products in endemic countries without private market), while on the users’ side there is a 
sense of frustration that things are not changing fast enough in the last decade, despite increased 
momentum currently spearheaded by WHO195. The current available mechanisms for enhancing 
access to VL drugs each have their drawbacks as discussed below.  
 Donation - In December 2011, Gilead Sciences agreed to donate 445,000 vials of 
AmBisome® (LAMB), managed by the WHO, for the treatment of ~50,000 VL patients. This 






was limited and strict. Though donations programmes are usually seen positively, they have their 
downsides. Companies may be motivated to donate because of the related tax reductions . In the 
specific case of LAMB, this large donation could discourage other companies to enter the market 
of alternative or generic LAMB formulations197. Extending the donation would only be a solution 
if it sustainably covered the needs of all leishmaniasis patients in developing countries who need 
LAMB. Donation of drug for NTD health programme is therefore laudable, yet sustainability and 
its unintended consequences must be mitigated114,198. The importance of drug donations in terms 
of cost-saving and reaching an elimination goal does not absolve the public health sector to 
develop the necessary long term vision.  
 Preferential pricing or tiered pricing. Amongst the leishmaniasis medicines, SSG and PM 
are currently sold at-cost or with negligible profit. AmBisome®, prior to the donation 
programme, was also available at a lower price for the public sector in VL endemic countries 
(US$20 per vial in 2006, and US$18 per vial in 2008). This tiered pricing may have increased 
access to LAMB in the Indian subcontinent, but was probably still too high for many health 
systems in developing countries (based on a cost-effectiveness study, this price has been called 
to be further reduced to US$10 per vial47). Knights also set up preferential pricing for MF for the 
non-profit sector, tied to the minimum order requirement to fulfil a batch production. This has 
proven to be quite a barrier for small procurers, and even more so since this price has been 
increasing over the years199. Tiered pricing is not advantageous when not pushed by a strong 
competitive environment, but rather by arbitrary divisions between markets and/or countries by 
the company, i.e. concentrating more decision-making power in the hands of sellers vis-à-vis 
consumers200.  
 Competition with generic producers – Currently, this does not exist for any of the 
leishmaniasis medicines. For antimonials, the generic SSG is produced by Albert David, India 
(there are also branded formulations, namely Pentostam® and Glucantime® but they are not 
used in Africa). Only perhaps for MF and LAMB there will be interest from other manufacturers 
as there exist lucrative potential sales for the other indications of LAMB than in occasional small-
scale public procurement for national leishmaniasis programmes201. For MF, with potential 
expansion of indication, including the Free Living Amoeba, or for possible higher demand for 
leishmaniasis in Latin America, there has been several expressions of interest, including generic 
producers in India and other. Despite the fact that more producers are welcome, the necessity to 
respect the quality requirements is also of utmost importance, and more engagement with 
schemes such as WHO Pre-Qualification Program (PQP), Expert Review Panel (ERP) and 
Collaborative Registration Procedure (CRP) is needed.  
 Coming back to our work, we laid out as well the perceived progress and actions moving 
forward. Several have been in place, yet need further refinement, e.g. a pooled procurement 
approach and establishment of a rotating stock for eastern Africa. Pooled procurement refers to 
arrangement where financial and non-financial resources are combined across various 
purchasing authorities to create a single entity for purchasing on behalf of the individual 
purchasing authorities202. Pooled procurement has been used at subnational, national and 
international levels such as for Human African Trypanosomiasis and to some extent as well in the 
Global Fund mechanism, but for leishmaniasis it has been largely underused. A regional approach 
towards tackling leishmaniasis in eastern Africa is already starting through annual exchange of 
information, but more efforts are needed to realise more concrete collaboration. New funding 
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injections through collaborative platforms such as KalaCORE could contribute to improving the 
supply chain and alternative strategies should be explored for eastern Africa. 
 In our view, the main stakeholders must come together in a more united front, define 
paths and mechanisms to strengthen the supply chain for leishmaniasis commodities, especially 
since no private market is involved.  
 As the diagnostics and medicines are delivered to the health facilities, now as the last 
phase of access, the patients should utilise them. It is important to reiterate from the outset that 
suboptimal access to leishmaniasis medicines is only one of the many challenges relating to 
people’s access to appropriate care. Patient access to adequate care depends on a range of factors 
such as financial resources, availability and skill set of health workforce, health care 
infrastructure and physical access to health services. As these factors are inextricably linked, 
many problems and challenges related to the provision of VL medicines are likely to be common 
across other parts of the health care system.  
 Our work in Article 5 explored the barriers faced by the community in Gadarif state in 
Sudan, using the Andersen’s health utilisation conceptual framework, complemented with the 
three delays model by Thaddeus&Maine203. A diverse population with large farming livelihood 
that attracts migrant workers even from the bordering north-west Ethiopia, Gadarif provides the 
mosaic needed to understand what the ‘suffering’ is all about when we speak of NTDs.  
 There has been relatively less evidence focusing on the worldview of patients’ and their 
families. Even if Gadarif has known leishmaniasis since the 1990s when an outbreak occurred in 
Barbar el Fugara village and has attracted scientific attention since, the interventions have 
focused on expanding the number of hospitals that provide VL care. Meanwhile, delay to seek care 
was attributed to low knowledge and financial barriers88. VL has its vernacular name in many 
contexts, including in the two river basins in Gadarif, and our work demonstrated that even if 
knowledge has increased, some misconceptions persisted.  
 The multiple trajectories in seeking care is also constrained by the various symptoms of 
VL (fever, splenomegaly, wasting – each requires its own remedy) and the difficulties in getting 
positive diagnosis. Multiple visits to health care providers were consistently needed to access VL 
diagnosis. The symbolic ‘Alhamdulillah’ or Praise be for Allah (God Bless) reflects the relief when 
finally, VL is diagnosed and treatment could be commenced. Furthermore, the RDT which remains 
positive for some years for VL patients appears not to be fully trusted by health providers in this 
endemic area. A paying, private lab in the Gadarif city has become the ‘de facto’ referent diagnostic 
laboratory. The use of RDTs use in VL endemic countries in eastern Africa is still not optimal and 
requires further study73. 
 The costs involved in VL care remain a significant barrier to seek care for the household, 
moreover during the rainy season when transport costs increase substantially. Lower priority 
when female family members are affected  ̶ a long-suspected gender bias ̶ may also have financial 
aspects in it123. Access has also become inequitably distributed between and within localities, as 
the quality of care in hospitals varies, including level of free-of-charge service that differs between 
NGO-supported hospitals and non-supported. Unavailability of trained staff and 
diagnostic/treatment demotivate people to seek care earlier.  
  Our study was conducted in concurrence with another qualitative study on migrant 






vulnerability to VL among the two populations, where the borders are illusory as in Sudan there 
are also residents engaging in transitory work. For the migrant workers in Ethiopia, the labour 
condition further complicates access, e.g. workers unable to receive salary advances, 
compensation for partial work, sick leave or simply permission to seek care when they fall ill. 
Decentralisation of diagnostic tests to primary healthcare facilities was called for.   
  Contrary to what is prescribed by national policy and guidelines, our study participants 
in Sudan reported poor access to diagnosis and, consequently, significantly delayed access to 
treatment. To reduce health disparities and the VL burden, interventions needs to be tailored to 
address the barriers at individual, society and health system levels outlined in our paper. Only 
when the complexities of individuals and households in relations to VL are really understood (and 
measured) are the needs of affected population likely to be prioritised and addresses.  
 
POLICY IMPLICATION, FUTURE RESEARCH AND PERSPECTIVES 
  An increased awareness towards NTDs has resulted in several milestones, including 
increased resources (such as pharmaceutical donations) and a more effective partnerships and 
governance205. Several milestones that are specific to (visceral) leishmaniasis is depicted in 
Figure 10 below. As we can see, the Indian sub-continent Kala-Azar Elimination programme has 
amassed significant political, financial and scientific commitments, while the endgame for eastern 
Africa is clearly still far.  
 
Figure 10. Chronogram of benchmarks in visceral leishmaniasis (adapted from Alves et al, 2018 and 
WHO Leishmaniasis timelines of fact: https://www.who.int/leishmaniasis/disease/Leishmaniasis-
interactive-timelines/en/). 
 The uptake of the policy recommendations issued in the seminal 2010 WHO technical 
guideline “Control of Leishmaniasis” was generally slow, and until date, no real breakthrough in 
novel control options has been seen in eastern Africa. Despite continued support and involvement 
from donors and international agencies, the disease remain hidden in remote rural areas and also 
largely silent, as the people affected or at risk have little political voice. NTDs traditionally rank 
low in national or international agenda, and leishmaniasis has been dubbed ‘neglect within 
neglect’ as it is not attributed the same level of resources or attention than other NTDs amenable 
to mass preventive chemotherapy. For all these reasons, leishmaniasis control needs to consider 
the full spectrum of access in the interventions. Whether a greater return on investment would 
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be gained from improving access to preventative interventions (e.g. vector control or others), 
than from access to newer, field-friendly medicines, remains to be seen.  
 Designation of ‘neglect’ stops being useful when nothing happens (CL is also considered 
as a ‘neglected’ leishmaniasis as compared to the fatal or severe forms), and as we can see in 
leishmaniasis R&D landscape, there are quite several positive developments whether specific or 
rather global (funding stream and flows, impacts of PPP and PDPs, advocacy towards fairer R&D 
system, etc). We described the importance of partnerships and collaborations (through which 
leishmaniasis has benefited), and nevertheless, a cautionary attitude is warranted, as MF case 
study has shown. Our work on access, both upstream and downstream, underlines the vital role 
of the governments (and public sector at large) to step up in owning up their responsibilities 
towards leishmaniasis patients.  
 Through our work we contend the following concluding messages; one, despite progress 
in NTDs response worldwide, for leishmaniasis there are inequalities in different parts of the 
word and eastern Africa has suffered the brunt of neglect. Access to care in this region urgently 
needs to be addressed in a more comprehensive way. Second, a promising pipeline of new 
chemical entities (NCEs) and repurposed therapies for leishmaniasis is not sufficient. The next 
decade should also do better in ensuring that new tools are accessible, affordable and available 
for the people who need them. Access is a multifaceted spectrum, and this should guide the efforts 
to tackle leishmaniasis. Political support is pivotal and continued advocacy will remain a 
necessity.  
 Our findings highlighted several further research priorities spelled out in each article. 
Several unanswered questions should be followed up with quantification approaches (such as for 
burden, or effectiveness of supply chain); while at the same time the view to understand the lived 
experiences and challenges that affect patients and their families need to be bolstered. Lastly, we 
propose to develop a better measure of progress in improving access to care for leishmaniasis in 
Africa based on components described in this thesis. Current monitoring efforts only focus on 
measurement of availability of medicines in health facilities, separate from measures of 
affordability which relied on information from stakeholders. Quality (of care, including the 
diagnosis and treatment) currently is difficult to assess due to absence of data. Improving access 
needs target measurements, a robust monitoring and accountability system – framework that has 
been called by Paul Hunt, former UN Special Rapporteur on the Right to Health206. The three steps 
include appropriate collection of data, independent review, and the necessary corrective action; 
these certainly can be adapted for leishmaniasis context in eastern Africa.  
 The table below summarises options and recommendations of actions that might enhance 














Registration of all leishmaniasis medicines in endemic countries ● ○ ◊ □
Regulatory pathways for diagnostics/medical devices ● ○ □
All leishmaniasis drugs are Pre-Qualified ● □
WHO treatment guidelines recommendations are adopted ● □ ◊
Regulatory harmonisation accross region ● □
Advocacy for leishmanaisis from national budget ● □ ◊ ◊
Improving availability
Drugs included in the National Medicine List are registered ● □
Implementation of forecasting/quantification platform, eg DHIS2 ● ○ □ ◊
Improve coordination and communication ● ○ □ □ □ □
Pooled procurement mechanisms for eastern Africa ○ ● □ ◊
Assess feasibility of integration of supply with essential medicines ● □ ◊
Increase coverage of care in endemic areas ● ◊ □
Improving quality
All leishmaniasis drugs undergo Pre-Qualification ● □
Adherence to the national clinical guidelines ● □ ◊
Increase capacity and skills in-country in clinical and pharmaecutical 
management ● □
Continued engagement with community to reduce delay in seeking care ● □ □
Improving affordability 
Policy to de-link price and cost of R&D, along with improved tranparency ○ ● □
Access plan included in the PDPs portfolio ● □
Realign R&D incentives such as PRV to the public health needs and impact ● □ □
Prepare sustainability plan after donation ○ ● □ ◊
More united front accross stakeholders when negotiating for better price ○ ● □ ◊ □
Leishmaniasis care included in the UHC package ● □ ◊
Mechanisms to reduce non medical costs of leishmaniasis ● □ ◊
Key:  
Time frame for action*Short term: within 1-5 year; medium term: 5–10 years; long term: more than 10 years. 
Proposed actions taken by:  Government Industry : 
Primary level of action ●; Complementary level of action  ○
Primary actor □; Complementary actors ◊












The current efforts to control visceral leishmaniasis (VL) in eastern Africa need to deal first and 
foremost with access to care, which sadly remains inadequate. Conflict-affected areas require 
innovative strategies. Developing improved diagnostic and treatment control tools is crucial, and so is 
ensuring that these tools reach the patients who need them the most. 
Our work provides these conclusions: 
1. Access to care in Somalia is limited due to its fragile context and more appropriate tools for 
such conflict-affected settings are urgently needed. 
2. Cutaneous leishmaniasis in sub-Saharan Africa has been overlooked and critical knowledge 
gaps remain. 
3. In endemic setting, the economic burden of leishmaniasis is still significant, and should be part 
of universal health care agenda.  
4. In current R&D landscape, the role of public private partnerships are important for 
leishmaniasis product development. However, the case study of miltefosine, the only oral drug, 
reminds us on the importance in ensuring access once a product receives market authorisation. 
5. In VL endemic area in Sudan, the community perspectives on access to care is far from 
satisfactory, and these insights should guide future intervention(s). 
6. Effective supply chain for leishmaniasis diagnostic and medicines in eastern Africa possesses 
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